Methods and agents for treating Alzheimer's disease

Activating the plasminogen activation pathway through administration of plasminogen or related compounds addresses the neurodegenerative symptoms of Alzheimer's by reducing amyloid beta deposition and improving cognitive function, providing a therapeutic benefit beyond current symptomatic treatments.

JP7576861B2Active Publication Date: 2024-11-01TALENGEN INTERNATIONAL LIMITED
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2022557662
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-24
Filing Date
2021-03-24
Publication Date
2024-11-01
Estimated Expiration
2041-03-24

AI Technical Summary

Technical Problem

Current treatments for Alzheimer's disease are primarily symptomatic and do not address the underlying progression of the disease, lacking effective methods to prevent or treat the neurodegenerative symptoms and cognitive decline.

Method used

Administering components of the plasminogen activation pathway, such as plasminogen or related compounds, to activate or upregulate plasminogen activity, thereby promoting the degradation of amyloid beta proteins and improving cognitive function and memory in Alzheimer's patients.

Benefits of technology

Plasminogen activation pathway components significantly reduce amyloid beta deposition, improve memory and cognitive function, and alleviate clinical symptoms of Alzheimer's disease, offering a potential therapeutic approach beyond symptomatic relief.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007576861000003
    Figure 0007576861000003
  • Figure 0007576861000004
    Figure 0007576861000004
  • Figure 0007576861000005
    Figure 0007576861000005
Patent Text Reader

Abstract

The present invention provides methods and medicaments for preventing and treating Alzheimer's disease, comprising administering to a subject a therapeutically effective amount of a component of the plasminogen activation pathway. The present invention also provides medicaments, pharmaceutical compositions, products, and kits comprising the component of the plasminogen activation pathway.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for preventing or treating Alzheimer's disease comprising administering to a subject an effective amount of a component of the plasminogen activation pathway or a related compound, such as plasminogen, to ameliorate clinical symptoms and signs. [Background technology]

[0002] Alzheimer's disease (AD) is a progressive neurodegenerative disease that develops insidiously. Clinically, it is characterized by generalized dementia, including memory impairment, aphasia, apraxia, agnosia, impairment of visuospatial abilities, executive dysfunction, and personality and behavioral changes, but its cause is still unknown. The main symptoms are cognitive decline, psychiatric symptoms and behavioral disorders, and a gradual decline in daily living abilities. It is divided into three stages depending on the degree of decline in cognitive ability and physical function. The first stage usually lasts 1 to 3 years and is characterized by mild dementia. Memory loss, with a notable forgetting of recent events; impaired judgment, inability to analyze events, think, or make decisions, and difficulty dealing with complex problems; inattentiveness at work and in household chores, inability to shop for oneself, financial matters, etc., and difficulty socializing; still able to perform some familiar everyday tasks, but absent-minded and unable to comprehend new things, emotionally disinterested, sometimes irritable, and often suspicious; impaired temporal orientation, able to orient to places and people, but difficulty grasping the geographic location of those places, poor visuospatial ability for complex structures; small verbal vocabulary, and difficulty with naming. The second stage usually lasts 2-10 years and is characterized by moderate dementia. It presents with severe impairment of distant and near memory, reduced visuospatial abilities of simple structures, and impaired orientation in time and place; severe impairment in dealing with problems and distinguishing between similarities and differences in things; inability to perform outdoor activities independently and needing assistance with dressing, personal hygiene, and maintaining appearance; inability to calculate; various neurological symptoms such as aphasia, apraxia, and agnosia; affect varies from apathy to irritability, and is often manifested as gait disturbance and urinary incontinence. The third stage, usually lasting 8-12 years, is the stage of severe dementia. The patient is completely dependent on the caregiver, has severe memory loss, and has only fragmented memories; is unable to care for himself in daily life, is incontinent, mutism, and rigidity of the limbs; physical examination reveals positive pyramidal signs with primitive reflexes such as grasping, groping, and sucking. The patient eventually lapses into a coma and usually dies from complications such as infection.

[0003] Current treatments are mainly symptomatic treatments to control the psychopathological symptoms associated with Alzheimer's disease. For example, anti-anxiety drugs are administered if there are symptoms of anxiety, agitation, and insomnia, antidepressants are administered if there are symptoms of depression, and antipsychotics are administered to control the patient's behavioral disorders. In addition, nootropics and cognitive function-improving drugs, such as drugs that act on neurotransmitters, cerebral vasodilators, and drugs that promote brain metabolism, are administered to improve cognitive function and slow the progression of the disease. Other therapies and drugs need to be found for the treatment of Alzheimer's disease. Summary of the Invention

[0004] Through research, the present invention has discovered that plasminogen can promote the recovery of memory function in Alzheimer's disease patients, improve cognitive ability, significantly alleviate and alleviate various clinical symptoms and signs of Alzheimer's disease, and prevent and treat Alzheimer's disease.

[0005] Specifically, the present invention relates to the following:

[0006] In one aspect, the present application relates to a method of preventing and treating Alzheimer's disease comprising administering to a subject with Alzheimer's disease a therapeutically effective amount of one or more compounds selected from components of the plasminogen activation pathway, compounds that can activate plasminogen directly or indirectly by activating upstream components of the plasminogen activation pathway, compounds that mimic the activity of plasminogen or plasmin, compounds that can upregulate the expression of plasminogen or plasminogen activators, plasminogen analogs, plasmin analogs, tPA or uPA analogs, and antagonists of fibrinolytic inhibitors.

[0007] In one aspect, the present application relates to the use of one or more compounds selected from components of the plasminogen activation pathway, compounds that can activate plasminogen directly or indirectly by activating upstream components of the plasminogen activation pathway, compounds that mimic the activity of plasminogen or plasmin, compounds that can upregulate the expression of plasminogen or plasminogen activators, plasminogen analogs, plasmin analogs, tPA or uPA analogs, and antagonists of fibrinolysis inhibitors in the preparation of a medicament for treating Alzheimer's disease.

[0008] In one aspect, the present application relates to an agent or pharmaceutical composition for treating Alzheimer's disease comprising one or more compounds selected from a component of the plasminogen activation pathway, a compound that can activate plasminogen directly or indirectly by activating an upstream component of the plasminogen activation pathway, a compound that mimics the activity of plasminogen or plasmin, a compound that can upregulate the expression of plasminogen or a plasminogen activator, a plasminogen analog, a plasmin analog, a tPA or uPA analog, and an antagonist of a fibrinolysis inhibitor.

[0009] 2. The method, use, agent or pharmaceutical composition according to item 1, wherein the component of the plasminogen activation pathway is selected from plasminogen, recombinant human plasminogen, Lys-plasminogen, Glu-plasminogen, plasmin, plasminogen and plasmin variants and analogs containing one or more kringle domains and protease domains of plasminogen and plasmin, mini-plasminogen, mini-plasmin, micro-plasminogen, micro-plasmin, delta-plasminogen, delta-plasmin, plasminogen activators, tPA and uPA.

[0010] 3. The method, use, agent or pharmaceutical composition according to item 1, wherein the fibrinolysis inhibitor antagonist is an inhibitor of PAI-1, complement C1 inhibitor, alpha2-antiplasmin or alpha2-macroglobulin, such as an antibody.

[0011] 4. The method, use, agent, or pharmaceutical composition according to any one of items 1 to 3, wherein the compound has one or more activities selected from the following for a subject with Alzheimer's disease: promoting degradation of amyloid Aβ40 or Aβ42 in brain tissue; improving memory function; improving cognitive ability; improving geographical location recognition; alleviating anxiety or depression symptoms; reducing Aβ42 deposition in brain tissue; promoting degradation of Tau protein in brain tissue; promoting the formation of mature BDNF by cleavage of Pro-BDNF in brain tissue; promoting the expression of BDNF in brain tissue; promoting the formation of mature NGF by cleavage of Pro-NGF in brain tissue; and improving hippocampal damage in brain tissue.

[0012] 5. The method, use, medicament, or pharmaceutical composition according to any one of items 1 to 4, wherein the compound is plasminogen.

[0013] 6. The method, use, agent, or pharmaceutical composition according to any one of items 1 to 5, wherein the plasminogen is human full-length plasminogen or a conservatively substituted variant thereof.

[0014] 7. The method, use, agent or pharmaceutical composition according to any one of items 1 to 5, wherein the plasminogen has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with sequence 2 and still has plasminogen lysine binding activity or proteolytic activity.

[0015] 8. The method, use, agent or pharmaceutical composition according to any one of items 1 to 5, wherein the plasminogen comprises an amino acid sequence having at least 80%, 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity with sequence 14 and still has plasminogen proteolytic activity.

[0016] 9. The method, use, agent, or pharmaceutical composition according to any one of items 1 to 5, wherein the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, miniplasminogen, microplasminogen, delta-plasminogen, or mutants thereof that retain the proteolytic activity of plasminogen.

[0017] 10. The method, use, agent, or pharmaceutical composition according to any one of claims 1 to 5, wherein the plasminogen comprises the amino acid sequence shown in sequence 2, 6, 8, 10 or 12, or comprises a conservatively substituted variant of the amino acid sequence shown in sequence 2, 6, 8, 10 or 12.

[0018] 11. The method, use, medicament, or pharmaceutical composition according to any one of items 1 to 10, wherein the compound is used in combination with one or more other therapeutic methods or medicaments.

[0019] 12. The method, use, medicament or pharmaceutical composition according to item 11, wherein the other treatment methods include cell therapy (including stem cell therapy), supportive therapy, and physical therapy.

[0020] 13. The method, use, agent, or pharmaceutical composition according to item 11, wherein the other agent is an agent for the treatment of Alzheimer's disease.

[0021] 14. The method, use, medicament, or pharmaceutical composition according to any one of items 1 to 13, wherein the compound is administered by nasal inhalation, aerosol inhalation, nasal drops, eye drops, ear drops, intravenous, intraperitoneal, subcutaneous, intracranial, intrathecal, intraarterial (e.g. via the carotid artery), and intramuscular administration.

[0022] In any one of the above embodiments of the present application, the plasminogen may have at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with sequence 2, 6, 8, 10 or 12 and still have plasminogen activity, for example, lysine binding activity or proteolytic activity. In some embodiments, the plasminogen is a protein in which 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid is added, deleted, and / or substituted based on sequence 2, 6, 8, 10 or 12 and still have plasminogen activity, for example, lysine binding activity or proteolytic activity.

[0023] In some embodiments, the plasminogen is a protein that includes plasminogen fragments and still has plasminogen activity, e.g., proteolytic activity. In some embodiments, the plasminogen is Glu-plasminogen, Lys-plasminogen, miniplasminogen, microplasminogen, δ-plasminogen, or a variant thereof that retains plasminogen activity, e.g., proteolytic activity. In the above embodiments, the plasminogen is natural or synthetic human plasminogen, or a variant or fragment thereof that still retains plasminogen activity, e.g., lysine-binding activity or proteolytic activity. In some embodiments, the plasminogen is an orthologue of human plasminogen from a primate or rodent, or a variant or fragment thereof that still retains plasminogen activity, e.g., lysine-binding activity or proteolytic activity. In some embodiments, the amino acid of the plasminogen is shown in sequence 2, 6, 8, 10, or 12. In some embodiments, the plasminogen is human natural plasminogen.

[0024] In some embodiments, the subject is a human. In some embodiments, the subject is deficient or lacking in plasminogen. In some embodiments, the deficient or lacking is congenital, inherited and / or localized.

[0025] In some embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier and plasminogen for use in the aforementioned methods. In some embodiments, the kit may be a prophylactic or therapeutic kit comprising (i) plasminogen for use in the aforementioned methods, and (ii) means for delivering the plasminogen to the subject. In some embodiments, the means is a syringe or a vial. In some embodiments, the kit further comprises a label or a protocol for instructing administration of the plasminogen to the subject to perform any of the aforementioned methods.

[0026] In some embodiments, the article of manufacture comprises a container containing a label and (i) plasminogen or a pharmaceutical composition containing plasminogen for use in the aforementioned methods, the label providing instructions for administering the plasminogen or composition to the subject to perform any of the aforementioned methods.

[0027] In some embodiments, the kit or article of manufacture further comprises one or more additional components or containers that contain other agents.

[0028] In some embodiments of the method, the plasminogen is administered systemically or locally, preferably by intravenous, intramuscular, or subcutaneous administration of plasminogen. In some embodiments of the method, the plasminogen is administered in combination with a suitable polypeptide carrier or stabilizer. In some embodiments of the method, the plasminogen is administered at a daily dose of 0.0001-2000 mg / kg, 0.001-800 mg / kg, 0.01-600 mg / kg, 0.1-400 mg / kg, 1-200 mg / kg, 1-100 mg / kg, 10-100 mg / kg (calculated per kilogram of body weight), or 0.0001-2000 mg / cm 2 , 0.001-800mg / cm 2 , 0.01-600mg / cm 2 , 0.1-400mg / cm 2 , 1-200mg / cm 2 , 1-100mg / cm 2 , 10-100mg / cm 2 (calculated per square centimeter of body surface area) and is preferably administered one or more times, preferably at least daily.

[0029] The present invention expressly covers all combinations of the technical features belonging to the embodiments of the present invention, and the technical configurations after the combinations are expressly disclosed in this application as if the above technical configurations were separately expressly disclosed. Moreover, the present invention also expressly covers the combinations between each embodiment and their elements, and the technical configurations after the combinations are expressly disclosed in this specification. [Brief description of the drawings]

[0030] [Figure 1]Figure 1A-B shows the results of Tricine-SDS electrophoresis of plasminogen dissolving amyloid Aβ40 in a PBS buffer system. A is Tricine-SDS-PAGE, and B is the result of quantitative scan analysis of Aβ40 dissolution in vitro. As a result, the amount of Aβ40 in the solvent control group was defined as 100%, and there was no change, in the plasminogen group, Aβ40 was partially degraded when only plasminogen was added, and in the plasminogen + tPA group, when plasminogen and tPA were added, the in vitro degradation of Aβ40 was obvious, and there was a significant difference compared with the solvent control group (** represents P<0.01). This indicates that plasminogen can promote the degradation of Aβ40. [Diagram 2] Figure 2A-B shows the results of Tricine-SDS electrophoresis of plasminogen dissolving amyloid Aβ40 in rabbit cerebrospinal fluid, where lanes 1 and 4 are blank control groups, lane 2 is the solvent group, and lane 3 is the plasminogen group. A is the result of Tricine-SDS-PAGE, and B is the result of quantitative scanning analysis of Aβ40 dissolution. As a result, the amount of Aβ40 in the solvent control group was defined as 100%, and there was no change, while in the plasminogen group, Aβ40 was partially degraded when only plasminogen was added, and it was degraded to 74.81%. This indicates that plasminogen can promote the degradation of Aβ40. [Diagram 3] Figure 3A-B shows the results of the effect of plasminogen on human amyloid Aβ40 in rabbit cerebrospinal fluid. A is a diagram of Tricine-SDS-PAGE electrophoresis, and B is the result of quantitative scan analysis of Aβ40 dissolution. As a result, the amount of Aβ40 in the solvent control group was defined as 100%, and there was no change, while in the plasminogen group, Aβ40 was partially degraded when only plasminogen was added, degraded to 74.81%. This indicates that plasminogen can promote the degradation of human amyloid Aβ40 in rabbit cerebrospinal fluid. [Figure 4]4A-B show the results of the effect of plasminogen on human amyloid Aβ40 in Alzheimer's disease models and normal mouse brain homogenates. A is a diagram of Tricine-SDS-PAGE electrophoresis, and B is the result of quantitative scanning analysis of Aβ40 dissolution in vitro. As a result, in the brain homogenates of FAD mice, the amount of amyloid Aβ40 in the treatment group was significantly lower than that in the solvent control group, and the difference was highly significant (*** indicates P<0.001); in the brain homogenates of normal mice, the amount of human amyloid Aβ40 in the treatment group was significantly lower than that in the solvent control group, and the difference was highly significant (P=0.001). This indicates that plasminogen can effectively promote the degradation of human amyloid Aβ40 in Alzheimer's disease models and normal mouse brain homogenates. [Diagram 5] 5 shows the statistical results of the spontaneous alternation rate (%) in Alzheimer's disease model mice 5 days after administration of plasminogen. As a result, the spontaneous alternation rate of the mice in the vehicle group was significantly increased compared with the normal control mice, and the spontaneous alternation rate of the mice in the administration group was significantly lower than that of the vehicle control group, with the statistical difference being significant (* indicates P<0.05) and closer to that of the normal control mice. [Figure 6] 6 is a diagram showing the statistical results of the total arm entry number of Alzheimer's disease model mice 5 days after plasminogen administration. As a result, the total arm entry number of the mice in the vehicle group was significantly decreased compared with the normal control mice, and the total arm entry number of the mice in the plasminogen administration group was significantly higher than that of the mice in the vehicle group, with a significant statistical difference (* indicates P<0.05), closer to the normal control mice. [Figure 7] Figure 7 shows the statistical results of the total movement distance of Alzheimer's disease model mice 5 days after plasminogen administration. As a result, compared with the normal control mice, the total movement distance of the mice in the solvent group was significantly decreased, and the total movement distance of the mice in the plasminogen group was significantly longer than that of the mice in the solvent control group, with a significant statistical difference (* indicates P<0.05), closer to the normal control mice. [Figure 8]8A-C are diagrams showing the quantitative analysis results of Aβ42 staining in the cerebral cortex after 28 days of administration of plasminogen to Alzheimer's disease model mice. A is the vehicle group, B is the treatment group, and C is the quantitative analysis result of the average optical density. As a result, the deposition level of Aβ42 in the cerebral cortex of mice in the vehicle group was significantly higher than that of the treatment group, and the statistical difference of the quantitative analysis results of the optical density was significant (* represents P<0.05). This suggests that plasminogen can reduce the deposition of Aβ42 in the cerebral cortex of Alzheimer's disease model mice. [Figure 9] 9A-B show the results of Western blot of Aβ42 in brain tissue homogenates of Alzheimer's disease model mice after administration of plasminogen for 8 days. A is a representative image of Western blot, and B is the result of quantitative analysis of optical density. As a result, there was a certain level of Aβ42 protein in the brain homogenates of mice in the blank control group, and the level of Aβ42 in the brain tissues of mice in the solvent group was significantly higher than that of mice in the treatment group, with a statistical P value of 0.09. This indicates that plasminogen can reduce the level of Aβ42 in the brain tissues of Alzheimer's disease model mice. [Figure 10] Figure 10A-B shows the effect of plasminogen on Tau protein in normal mouse brain homogenate. A is a Western blot image, and B is the quantitative analysis result of the optical density of Tau protein band. As a result, in normal mouse brain homogenate, the amount of Tau protein in the plasminogen group was significantly lower than that in the solvent control group, and the difference was significant (* represents P<005, ** represents P<0.01, *** represents P<0.001). This suggests that plasminogen can promote the degradation of Tau protein in normal mouse brain homogenate. [Figure 11]11A-B are diagrams showing the effect of plasminogen on Tau protein in brain homogenates of Alzheimer's disease mice. A is a Western blot image, and B is the quantitative analysis result of the optical density of the Tau protein band. As a result, in the brain homogenates of Alzheimer's disease mice, the amount of Tau protein in the plasminogen group was significantly lower than that in the solvent control group, and the difference was statistically significant (* represents P<005, ** represents P<0.01). This suggests that plasminogen can promote the degradation of Tau protein in the brain homogenates of Alzheimer's disease mice. [Figure 12] Figure 12 shows the Western blot detection results of Tau proteins of different molecular weights in the brain tissue of Alzheimer's disease mice administered plasminogen for 28 days. The results showed that there was a certain level of Tau proteins of different molecular weights in the brain homogenate of mice in the blank control group, and the levels of Tau proteins of each molecular weight and total Tau protein in the brain tissue of mice in the administration group were significantly lower than those of mice in the vehicle group, and the statistical analysis P values ​​of 35kd, 35-40kd, 40kd, and 54kd molecular weight Tau protein levels and total Tau protein levels of the two groups were 0.174, 0.0406, 0.052, 0.067, and 0.055. This indicates that plasminogen can promote the degradation of Tau protein in the brain tissue of Alzheimer's model mice. [Figure 13] 13A-B are diagrams showing the effect of plasminogen on recombinant human Pro-BDNF in brain homogenates of Alzheimer's disease model mice. A is an image of SDS-PAGE, and B is the quantitative analysis result of the Pro-BDNF band in SDS-PAGE. As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of Pro-BDNF in the plasminogen administration group was significantly lower than that in the solvent control group, and the difference was highly significant (* indicates P<0.05, *** indicates P<0.001). This suggests that plasminogen can promote the cleavage of Pro-BDNF in the brain homogenates of Alzheimer's disease model mice. [Figure 14]14A-C are figures showing the effect of plasminogen on recombinant human Pro-BDNF in brain homogenates of Alzheimer's disease model mice, where A is an image of a Western blot, B is an analysis result of the optical density (OD) value of the Pro-BDNF band in the Western blot, and C is an analysis result of the optical density (OD) value of the BDNF band in the Western blot. As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of Pro-BDNF in the plasminogen administration group was significantly lower than that in the solvent control group, and the difference was highly significant (** indicates P<0.01, *** indicates P<0.001); the amount of BDNF in the plasminogen administration group was significantly higher than that in the solvent control group, and the difference was highly significant. This suggests that plasminogen can promote the cleavage of Pro-BDNF and the formation of mature BDNF in the brain homogenates of Alzheimer's disease model mice. [Figure 15] Figure 15A-D shows the results of immunohistochemical staining of BDNF in the hippocampus of Alzheimer's disease model mice administered plasminogen for 28 days. A is the blank control group, B is the solvent group, C is the treatment group, and D is the quantitative analysis result of the average optical density. The results showed that the hippocampus of the mice in the blank control group expressed a certain level of BDNF (marked with arrows), the expression of BDNF in the hippocampus of the mice in the solvent group was significantly lower than that of the blank control group, and the expression of BDNF in the hippocampus of the mice in the treatment group was significantly higher than that of the solvent group, and the statistical difference was significant (* represents P<0.05). This indicates that plasminogen can promote the expression of BDNF in the hippocampus of Alzheimer's disease model mice. [Figure 16]16A-C are diagrams showing the effect of plasminogen on recombinant human Pro-NGF in brain homogenates of Alzheimer's disease model mice. A is an image of a Western blot, B is an analysis result of the optical density (OD) value of the Pro-NGF band in the Western blot, and C is an analysis result of the optical density (OD) value of the NGF band in the Western blot. As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of Pro-NGF in the plasminogen administration group was significantly lower than that in the solvent control group, and the difference was highly significant (*** indicates P<0.001); the amount of NGF in the plasminogen administration group was significantly higher than that in the solvent control group, and the difference was significant. This suggests that plasminogen can promote the cleavage of recombinant human Pro-NGF and the formation of mature NGF in the brain homogenates of Alzheimer's disease model mice. [Figure 17] Figure 17 shows the statistical results of the percentage (%) of the distance traveled in the border zone in the open field test of Alzheimer's disease model mice 28+7 days after administration of plasminogen. As a result, the blank control group had a certain percentage of the distance traveled in the border zone, the percentage of the distance traveled in the border zone of the solvent group mice was significantly higher than that of the blank control group, and the percentage of the distance traveled in the border zone of the treatment group mice was significantly lower than that of the solvent group, and the statistical difference was close to significance (P=0.08). This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 18] Figure 18 shows the statistical results of the percentage (%) of the distance traveled in the central zone in the open field test of Alzheimer's disease model mice 28+7 days after plasminogen administration. As a result, the blank control group had a certain percentage of the distance traveled in the central zone, the percentage of the distance traveled in the central zone of the vehicle group mice was significantly smaller than that of the blank control group, and the percentage of the distance traveled in the central zone of the administration group mice was significantly larger than that of the vehicle group, and the statistical difference was close to significance (P=0.08). This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 19]Figure 19 shows the statistical results of the total movement distance in the elevated plus maze test of Alzheimer's disease model mice 28+7 days after plasminogen administration. The results showed that the blank control group had a constant total movement distance, the movement distance of the solvent group was significantly greater than that of the blank control group, and the total movement distance of the treatment group was significantly smaller than that of the solvent group, and the statistical difference was highly significant (* represents P<0.05, ** represents P<0.01), and was closer to the total movement distance of the mice in the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 20] Figure 20 shows the statistical results of the closed arm movement distance in the elevated plus maze test of Alzheimer's disease model mice 28+9 days after plasminogen administration. The results showed that the blank control group mice had a certain closed arm movement distance, the closed arm movement distance of the solvent group was significantly larger than that of the blank control group, and the closed arm movement distance of the treatment group was significantly smaller than that of the solvent group, and the statistical difference between the two groups was significant (* represents P<0.05, ** represents P<0.01), and the closed arm movement distance of the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 21] Figure 21 shows the statistical results of the percentage of closed arm movement distance in the elevated plus maze test of Alzheimer's disease model mice 28+9 days after plasminogen administration. The results showed that the blank control group mice had a certain percentage of closed arm movement distance, the percentage of closed arm movement distance of the solvent group was significantly larger than that of the blank control group, and the percentage of closed arm movement distance of the treatment group was significantly smaller than that of the solvent group, and the statistical difference between the two groups was significant (* represents P<0.05), and the percentage of closed arm movement distance of the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 22]Figure 22 shows the statistical results of the closed arm entry frequency in the elevated plus maze test of Alzheimer's disease model mice 28+9 days after plasminogen administration. The results showed that the blank control group mice had a certain closed arm entry frequency, the closed arm entry frequency of the solvent group mice was significantly higher than that of the blank control group mice, and the closed arm entry frequency of the treatment group mice was significantly lower than that of the solvent group, and the statistical difference between the two groups was highly significant (* represents P<0.05, ** represents P<0.01), and the closed arm entry frequency of the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 23] Figure 23 shows the statistical results of the closed arm time in the elevated plus maze test of Alzheimer's disease model mice 28+9 days after plasminogen administration. The results showed that the blank control group mice had a constant closed arm time, the time spent in the closed arm of the vehicle group mice was significantly shorter than that of the blank control group mice, and the time spent in the closed arm of the treatment group mice was significantly longer than that of the vehicle group, and the statistical difference between the two groups was significant (* represents P<0.05, ** represents P<0.01), and the time spent in the closed arm of the treatment group was closer to that of the blank control group. [Figure 24] FIG. 24 is a diagram showing the statistical results of the percentage of closed arm time in the elevated plus maze test of Alzheimer's disease model mice 28+9 days after plasminogen administration. The percentage of closed arm time refers to the ratio of the time the mouse spent in the closed arm to the total time recorded. As a result, the blank control group mice had a constant percentage of closed arm time, the percentage of closed arm time of the solvent group mice was significantly lower than that of the blank control group mice, and the percentage of closed arm time of the treated group mice was significantly higher than that of the solvent group, and the statistical difference between the two groups was significant (* represents P<0.05, ** represents P<0.01), and the percentage of closed arm time of the treated group was closer to the blank control group. [Diagram 25]Figure 25 shows the statistical results of the average moving speed in the closed arms in the elevated plus maze test of Alzheimer's disease model mice 28+9 days after plasminogen administration. As a result, the blank control group mice had a constant average moving speed in the closed arms, the average moving speed in the closed arms of the solvent group was significantly higher than that of the blank control group mice, and the average moving speed in the closed arms of the treated group mice was significantly lower than that of the solvent group, and the statistical difference between the two groups was highly significant (** represents P<0.01), and the average moving speed in the closed arms of the treated group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 26] Figure 26 shows the statistical results of the spontaneous alternation behavior rate in the Y-maze of Alzheimer's disease model mice 28+9 days after plasminogen administration. As a result, the spontaneous alternation behavior rate of the mice in the solvent group was significantly decreased compared with the blank control mice, and the spontaneous alternation behavior rate of the mice in the treatment group was significantly higher than that of the solvent group, and the statistical difference between the two groups was significant (* represents P<0.05), and was closer to the blank control group. This suggests that plasminogen can promote the recovery of memory function in Alzheimer's disease model mice. [Figure 27] FIG. 27 shows the statistical results of the distance traveled in the closed arm in the elevated plus maze test of Alzheimer's disease model mice 18 days after administration of plasminogen. As a result, the blank control group mice had a constant distance traveled in the closed arm, the distance traveled in the closed arm of the solvent group was significantly smaller than that of the blank control group mice, and the distance traveled in the closed arm of the treated group mice was significantly larger than that of the solvent group, and the statistical difference between the two groups was significant (** represents P<0.01, *** represents P<0.001), and the distance traveled in the closed arm of the treated group was closer to that of the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. [Figure 28]Figure 28A-C shows representative photographs of HE staining of brain tissue of Alzheimer's disease model mice after administration of plasminogen for 8 days. A is the blank control group, B is the solvent control group, and C is the treatment group. As a result, the hippocampal tissue morphology of the mice in the blank control group was normal, and compared with the solvent group, the tissue damage morphology of the hippocampus of the treatment group was significantly improved. This indicates that plasminogen can improve hippocampal damage in Alzheimer's disease model mice. Detailed Description of the Invention

[0031] The fibrinolytic system, also called the fibrinolytic system, is a system of a series of chemicals involved in the process of fibrinolysis (fibrinolysis), mainly including plasminogen (PLG), plasmin, plasminogen activators, and fibrinolysis inhibitors. Plasminogen activators include tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). t-PA is a serine protease and is synthesized by vascular endothelial cells. t-PA activates plasminogen, a process that mainly occurs in fibrin. Urokinase-type plasminogen activator (u-PA) is produced by renal tubular epithelial cells and vascular endothelial cells and can directly activate plasminogen without the need for fibrin as a cofactor. Plasminogen (PLG) is synthesized in the liver. When blood clots, PLG is adsorbed in large quantities to the fibrin net and activated to plasmin by the action of t-PA or u-PA to promote fibrinolysis. Plasminase (PL) is a serine protease that degrades fibrin and fibrinogen, hydrolyzes various coagulation factors V, VIII, X, VII, XI, II, etc., converts plasminogen to plasmin, hydrolyzes complement, etc. Fibrinolysis inhibitors include plasminogen activator inhibitor (PAI) and α2-antithyplasmin (α2-AP). There are two main forms of PAI, PAI-1 and PAI-2, which can specifically bind to t-PA in a 1:1 ratio and inactivate t-PA while activating PLG. α2-AP is synthesized in the liver and binds to PL in a 1:1 ratio to form a complex, thereby inhibiting PL activity. FXIII covalently binds α2-AP to fibrin, thereby weakening the susceptibility of fibrin to PL. Substances that inhibit the activity of the fibrinolysis system in vivo include PAI-1, complement C1 inhibitor, α2-antiplasmin, and α2-macroglobulin.

[0032] As used herein, the term "a component of the plasminogen activation pathway" refers to a 1. Plasminogen, Lys-plasminogen, Glu-plasminogen, micro-plasminogen, delta-plasminogen, their variants or analogs; 2. Plasmin and its variants or analogues; and 3. Plasminogen activators, including, for example, tPA and uPA, as well as tPA or uPA variants and analogs that contain one or more domains of tPA or uPA, such as one or more of the kringle domain and the proteolytic domain.

[0033] The above "variants" of plasminogen, plasmin, tPA and uPA include all naturally occurring genetic variants of human and other mammalian forms of these proteins, as well as proteins having, for example, 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, 1 to 3, 1 to 2 or 1 amino acid added, deleted and / or substituted and still having plasminogen activity, plasmin activity, tPA or uPA activity. For example, a "variant" of plasminogen, plasmin, tPA or uPA includes, for example, mutants of these proteins resulting from substitution of 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3, 1-2, 1 conservative amino acids.

[0034] The "plasminogen variant" of the present invention covers a protein having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with sequence 2, 6, 8, 10 or 12 and still having plasminogen activity, e.g., lysine binding activity or proteolytic activity. For example, the "plasminogen variant" of the present invention can be a protein having 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, 1 to 3, 1 to 2, 1 amino acid added, deleted and / or substituted based on sequence 2, 6, 8, 10 or 12 and still having plasminogen activity, e.g., lysine binding activity or proteolytic activity. In particular, the plasminogen variants of the present invention include all naturally occurring genetic variants of human and other mammalian forms of these proteins, as well as mutants of these proteins obtained by conservative substitution of, for example, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3, 1-2, 1 amino acids.

[0035] The plasminogen of the present invention may be an orthologue of human plasminogen derived from a primate or rodent, or a variant which still retains plasminogen activity, e.g., lysine-binding activity or proteolytic activity, such as the plasminogen shown in sequences 2, 6, 8, 10 or 12, e.g., human native plasminogen shown in sequence 2.

[0036] The above-mentioned "analogs" of plasminogen, plasmin, tPA and uPA include compounds that provide substantially the same effect as plasminogen, plasmin, tPA or uPA, respectively.

[0037] The above "variants" and "analogs" of plasminogen, plasmin, tPA and uPA cover "variants" and "analogs" of plasminogen, plasmin, tPA and uPA that contain one or more domains (e.g., one or more kringle domains and a proteolytic domain). For example, "variants" and "analogs" of plasminogen cover plasminogen variants and analogs, such as mini-plasminogen, that contain one or more plasmin domains (e.g., one or more kringle domains and a proteolytic domain). "Variants" and "analogs" of plasmin cover plasmin "variants" and "analogs" such as mini-plasmin and delta-plasmin that contain one or more plasmin domains (e.g., one or more kringle domains and a proteolytic domain).

[0038] Whether the above-mentioned "mutants" or "analogs" of plasminogen, plasmin, tPA or uPA have the activity of plasminogen, plasmin, tPA or uPA, respectively, or whether they exert substantially the same effect as plasminogen, plasmin, tPA or uPA, respectively, can be measured by the level of activated plasmin activity using methods known in the art, such as enzymography, ELISA (enzyme-linked immunosorbent assay) and FACS (fluorescence-activated cell sorting). For example, the measurement can be performed with reference to the methods described in the following documents:Ny,A.,Leonardsson,G.,Hagglund,A.C,Hagglof,P.,Ploplis,V.A.,Carmeliet,P. and Ny,T. (1999). Ovulation inplasminogen-deficient mice. Endocrinology 140,5030-5035;Silverstein RL, Leung LL, Harpel PC, Nachman RL (November 1984). “Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator”. J. Clin. Invest. 74 (5): 1625-33;Gravanis I, Tsirka SE (February 2008). “Tissue-type plasminogen activator as a therapeutic target in stroke”. Expert Opinion on Therapeutic Targets. 12 (2): 159-70;Geiger M, Huber K, Wojta J, Stingl L, Espana F, Griffin JH, Binder BR (Aug 1989). “Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo”. Blood. 74 (2): 722-8。

[0039] In some embodiments of the present invention, the "component of the plasminogen activation pathway" of the present invention is plasminogen. In some embodiments, the plasminogen is human full-length plasminogen or a conservative mutant thereof that retains its plasminogen activity (e.g., its lysine-binding activity or proteolytic activity). In some embodiments, the plasminogen is Glu-plasminogen, Lys-plasminogen, miniplasminogen, microplasminogen, δ-plasminogen or a variant thereof that retains their plasminogen activity (e.g., their lysine-binding activity or proteolytic activity). In some embodiments, the plasminogen is natural or synthetic human plasminogen or a conservative mutant or fragment thereof that still retains plasminogen activity (e.g., its lysine-binding activity or proteolytic activity). In some embodiments, the plasminogen is an orthologue of human plasminogen from a primate or rodent, or a conservative mutant or fragment thereof that still retains plasminogen activity. In some embodiments, the plasminogen comprises an amino acid sequence as shown in sequence 2, 6, 8, 10 or 12. In some embodiments, the plasminogen comprises a conservative substitution sequence of the amino acid sequence shown in sequence 2, 6, 8, 10 or 12. In some embodiments, the amino acids of the plasminogen are shown in sequence 2, 6, 8, 10 or 12. In some embodiments, the plasminogen is a conservative substitution variant of the plasminogen shown in sequence 2, 6, 8, 10 or 12. In some embodiments, the plasminogen is human native plasminogen or a conservative variant thereof. In some embodiments, the plasminogen is human native plasminogen shown in sequence 2 or a conservative variant thereof.

[0040] "A compound capable of directly activating plasminogen or indirectly activating plasminogen by activating an upstream component of the plasminogen activation pathway" refers to any compound capable of directly activating plasminogen or indirectly activating plasminogen by activating an upstream component of the plasminogen activation pathway, including, for example, tPA, uPA, streptokinase, saruplase, alteplase, reteplase, tenecteplase, anistreplase, monteplase, lanoteplase, pamiteplase, and staphylokinase.

[0041] The "antagonist of fibrinolysis inhibitors" of the present invention is a compound that antagonizes, weakens, blocks, or prevents the action of fibrinolysis inhibitors, such as PAI-1, complement C1 inhibitor, α2-antiplasmin, and α2-macroglobulin. Said antagonists are antibodies to PAI-1, complement C1 inhibitor, α2-antiplasmin or α2-macroglobulin, or for example antisense RNA or miniRNA that blocks or downregulates the expression of PAI-1, complement C1 inhibitor, α2-antiplasmin or α2-macroglobulin, or compounds that occupy the binding site of PAI-1, complement C1 inhibitor, α2-antiplasmin or α2-macroglobulin but do not have the function of PAI-1, complement C1 inhibitor, α2-antiplasmin or α2-macroglobulin, or compounds that block the binding and / or activity domains of PAI-1, complement C1 inhibitor, α2-antiplasmin or α2-macroglobulin.

[0042] Plasmin is an important component of the plasminogen activation system (PA system). It is a broad-spectrum protease that can hydrolyze several components of the extracellular matrix (ECM), including fibrin, gelatin, fibronectin, laminin, and proteoglycans. Plasmin can also activate some pro-matrix metalloproteinases (pro-MMPs) to become active matrix metalloproteinases (MMPs). Thus, plasmin is an important upstream regulator of extracellular proteolysis. Plasmin is formed by proteolysis of plasminogen from two physiological PAs: tissue-type plasminogen activator (tPA) or urokinase plasminogen activator (uPA). Plasminogen is present at relatively high relative levels in plasma and other body fluids, and traditionally, it has been believed that the regulation of the PA system is mainly achieved by the synthesis and activity levels of PAs. The synthesis of the components of the PA system is tightly regulated by different factors, such as hormones, growth factors, and cytokines. In addition, there are specific physiological inhibitors of plasmin and PAs. The main inhibitor of plasmin is α2-antiplasmin. The activity of PAs is simultaneously inhibited by plasminogen activator inhibitor-1 (PAI-1) of uPA and tPA, and is regulated by plasminogen activator inhibitor-2 (PAI-2), which mainly inhibits uPA. Some cells have a uPA-specific cell surface receptor (uPAR) with direct hydrolytic activity.

[0043] Plasminogen is a single-chain glycoprotein consisting of 791 amino acids with a molecular weight of approximately 92 kDa. It is synthesized mainly in the liver and is present in large amounts in extracellular fluids. The plasminogen content in plasma is approximately 2 μM. Thus, plasminogen is a large potential source of proteolytic activity in tissues and body fluids. There are two molecular forms of plasminogen: glutamate-plasminogen (Glu-plasminogen) and lysine-plasminogen (Lys-plasminogen). The naturally secreted and undegraded form of plasminogen has one amino-terminal (N-terminal) glutamic acid and is therefore called glutamate-plasminogen. However, in the presence of plasmin, glutamate-plasminogen is hydrolyzed to lysine-plasminogen at Lys76-Lys77. Compared to glutamate-plasminogen, lysine-plasminogen has a higher affinity for fibrin and can be activated by PAs at a higher rate. The Arg560-Val561 peptide bond of the two forms of plasminogen is cleaved by uPA or tPA, leading to the formation of the disulfide-linked double-chain protease plasmin. The amino-terminal part of plasminogen contains five homologous tricycles, the so-called kringles, and the carboxyl-terminal part contains the protease domain. Some kringles contain a lysine-binding site that mediates the specific interaction of plasminogen with fibrin and its inhibitor α2-AP. The most recently discovered plasminogen is a 38 kDa fragment, containing kringlel-4, which is a potent inhibitor of angiogenesis. This fragment, named angiostatin, is generated from several protease-hydrolyzed plasminogens.

[0044] The main substrate of plasmin is fibrin, and fibrin lysis is a key point to prevent the formation of pathological thrombi. Plasmin also has substrate specificity for several components of the ECM, including laminin, fibronectin, proteoglycan, and gelatin, indicating that plasmin plays an important role in ECM reconstruction. Indirectly, plasmin also degrades other components of the ECM by converting some protease precursors, including MMP-1, MMP-2, MMP-3, and MMP-9, into active proteases. Therefore, it may be proposed that plasmin is an important upstream regulator of extracellular protein hydrolysis. Plasmin also has the ability to activate some latent forms of growth factors. In vitro, plasmin can also hydrolyze components of the complement system to release chemotactic complement fragments.

[0045] "Plasmin" is a very important enzyme present in blood, which hydrolyzes fibrin clots into fibrin degradation products and D-dimers.

[0046] "Plasminogen" is the proenzyme form of plasmin, which, based on the sequence in swiss prot, is calculated as the amino acid sequence of natural human plasminogen including the signal peptide (Sequence 4), and consists of 810 amino acids, has a molecular weight of about 90 kD, is synthesized mainly in the liver, and is a glycoprotein that can circulate in the blood, and the cDNA sequence encoding said amino acid sequence is as shown in Sequence 3. Full-sized plasminogen contains seven domains: a serine protease domain located at the C-terminus, a Pan Apple (PAp) domain located at the N-terminus, and five Kringle domains (Kringle 1-5). With reference to the sequence in swiss prot, the signal peptide comprises residues Met1-Gly19, PAp comprises residues Glu20-Val98, Kringle1 comprises residues Cys103-Cys181, Kringle2 comprises residues Glu184-Cys262, Kringle3 comprises residues Cys275-Cys352, Kringle4 comprises residues Cys377-Cys454, and Kringle5 comprises residues Cys481-Cys560. According to the NCBI data, the serine protease domain comprises residues Val581-Arg804.

[0047] Glu-plasminogen is a natural full-size human plasminogen, and consists of 791 amino acids (not including a signal peptide consisting of 19 amino acids). The cDNA sequence encoding this sequence is as shown in sequence 1, and its amino acid sequence is as shown in sequence 2. In vivo, Lys-plasminogen is formed by hydrolysis at the 76th-77th amino acid positions of Glu-plasminogen, and is, for example, as shown in sequence 6, and the cDNA sequence encoding this amino acid sequence is as shown in sequence 5. Delta-plasminogen (δ-plasminogen) is a fragment of full-size plasminogen lacking the Kringle2-Kringle5 structure, and contains only Kringle1 and a serine protease domain (also called the protease domain (PD)). There is a literature that reports the amino acid sequence of δ-plasminogen (sequence 8), and the cDNA sequence encoding this amino acid sequence is, for example, sequence 7. Mini-plasminogen consists of Kringle5 and serine protease domains, and the literature reports residues Val443-Asn791 (starting with the Glu residue of the Glu-plasminogen sequence without the signal peptide), and its amino acid sequence is as shown in sequence 10, and the cDNA sequence encoding this amino acid sequence is as shown in sequence 9. However, literature reports that microplasminogen only contains a serine protease domain, and its amino acid sequence is residues Ala543-Asn791 (the Glu residue of the Glu-plasminogen sequence without the signal peptide is the starting amino acid), and patent document CN102154253A discloses that it contains residues Lys531-Asn791 (the Glu residue of the Glu-plasminogen sequence without the signal peptide is the starting amino acid), and in this patent application, the sequence of microplasminogen can be referred to patent document CN102154253A, and its amino acid sequence is as shown in sequence 12, and the cDNA sequence encoding the amino acid sequence is as shown in sequence 11.

[0048] The structure of full-length plasminogen is also described in a paper by Aisina et al. (Aisina RB, Mukhametova L I. Structure and function of plasminogen / plasmin system[J]. Russian Journal of Bioorganic Chemistry, 2014, 40(6):590-605). According to the above mentioned article by Aisina et al., plasminogen contains Kringle 1, 2, 3, 4, 5 domains and a serine protease domain (also called protease domain (PD)), Kringles are responsible for binding plasminogen to low and high molecular weight ligands (i.e., lysine binding activity), which results in the conversion of plasminogen to a more open configuration and makes it more accessible to activation, and the protease domain (PD) is residues Val562-Asn791, and tPA and UPA specifically cleave the Arg561-Val562 activating bond of plasminogen, thereby allowing plasminogen to form plasmin. Thus, the protease domain (PD) is the region that confers the proteolytic activity of plasminogen.

[0049] In the present invention, "plasmin", "fibrin plasmin", and "fibrous protein plasmin" can be used interchangeably and have the same meaning. "Plasminogen", "fibrin plasminogen", and "fibrous protein plasminogen" can be used interchangeably and have the same meaning.

[0050] In this application, the "insufficiency" of plasminogen refers to the content or activity of plasminogen in the subject's body being lower than that of a normal person and being low enough to affect the subject's normal physiological function. The meaning of "deficiency" of plasminogen is that the content or activity of plasminogen in the subject's body is obviously lower than that of a normal person, the activity or expression is extremely low, and normal physiological function can only be maintained by external supply.

[0051] Those skilled in the art can understand as follows. All technical configurations of plasminogen in the present invention can be applied to plasmin, so the technical configurations described in the present invention cover plasminogen and plasmin. In the circulation process, plasminogen takes a closed inactive conformation, but when it binds to a thrombus or cell surface, it becomes active plasmin with an open conformation under the mediation of plasminogen activator (PA). The active plasmin further hydrolyzes fibrin clots into fibrin degradation products and D-dimers, thereby dissolving the thrombus. Among them, the PAp domain of plasminogen contains an important epitope that maintains plasminogen in an inactive closed conformation, but the KR domain can bind to lysine residues on receptors and substrates. Several types of enzymes as plasminogen activators have already been known, including tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and coagulation factor XII (Hagemann factor), etc.

[0052] "Plasminogen active fragment" refers to an active fragment that binds to lysine in the target sequence of a substrate (lysine binding activity), or an active fragment that exerts a proteolytic function (proteolytic activity), or a fragment that has both proteolytic activity and lysine binding activity. The plasminogen technical configuration of the present invention encompasses technical configurations that replace plasminogen with a plasminogen active fragment. In some embodiments, the plasminogen active fragment of the present invention comprises the serine protease domain of plasminogen or consists of the serine protease domain of plasminogen. In some embodiments, the plasminogen active fragment of the present invention comprises sequence 14, or comprises an amino acid sequence having at least 80%, 90%, 95%, 96%, 97%, 98%, 99% identity to sequence 14, or consists of an amino acid sequence having at least 80%, 90%, 95%, 96%, 97%, 98%, 99% identity to sequence 14. In some embodiments, the plasminogen active fragment of the present invention comprises one or more domains selected from Kringle 1, Kringle 2, Kringle 3, Kringle 4, and Kringle 5, or conservative substitution variants thereof, or consists of one or more domains selected from Kringle 1, Kringle 2, Kringle 3, Kringle 4, and Kringle 5, or conservative substitution variants thereof. In some embodiments, the plasminogen of the present invention comprises a protein comprising an active fragment of plasminogen as described above.

[0053] At present, the methods for measuring plasminogen and its activity in blood include tissue plasminogen activator activity (t-PAA), plasma tissue plasminogen activator antigen (t-PAAg), plasma tissue plasminogen activity (plgA), plasma tissue plasminogen antigen (plgAg), plasma tissue plasminogen activator inhibitor activity, plasma tissue plasminogen activator inhibitor antigen, and plasma plasmin-antiplasmin complex (PAP). The most common method is the chromogenic substrate method: streptokinase (SK) and luminescent substrate are added to the plasma of the subject, and the PLG in the subject's plasma becomes PLM under the action of SK, which acts on the luminescent substrate, and then measured by a spectrophotometer, and the increase in absorbance is directly proportional to the activity of plasminogen. In addition, immunochemical methods, gel electrophoresis, immunoturbidimetry, radial immunodiffusion, etc. can also be used to measure plasminogen activity in blood.

[0054] "Ortholog" refers to a homologue between different species, including both protein and DNA homologues, also called a direct lineage gene. It specifically refers to a protein or gene that is evolved from the same ancestral gene between different species. The plasminogen of the present invention includes human native plasminogen, and further includes orthologs or orthologs of plasminogens with plasminogen activity derived from different species.

[0055] A "conservative substitution variant" is a variant in which a given amino acid residue is modified but does not change the overall conformation and function of a protein or enzyme, including but not limited to those that substitute an amino acid in the amino acid sequence of a parent protein with an amino acid of similar properties (e.g., acidic, alkaline, hydrophobic, etc.). Amino acids with similar properties are known. For example, arginine, histidine, and lysine are hydrophilic alkaline amino acids and can be substituted for each other. Similarly, isoleucine is a hydrophobic amino acid and can be substituted by leucine, methionine, or valine. Therefore, the similarity of two proteins or amino acid sequences with similar functions may vary. For example, they have a similarity (identity) of 70% to 99% based on the MEGALIGN algorithm. "Conservative substitution variants" further include polypeptides or enzymes with an amino acid identity of 60% or more based on the BLAST or FASTA algorithm, preferably 75% or more, most preferably 85% or more, and most preferably 90% or more, and have the same or essentially similar properties or functions compared to the natural or parent protein or enzyme.

[0056] "Isolated" plasminogen is plasminogen protein that has been separated and / or recovered from its natural environment. In some embodiments, the plasminogen is (1) purified to greater than 90%, greater than 95%, or greater than 98% purity (by weight), e.g., greater than 99% (by weight), as determined by the Lowry method; (2) purified to at least 15 residues of N-terminal or internal amino acid sequence as determined by a spinning cup sequencer; or (3) purified to homogeneity, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing conditions with Coomassie brilliant blue or silver staining. Isolated plasminogen includes plasminogen produced from recombinant cells by bioengineering techniques and separated by at least one further purification step.

[0057] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length, including genetically encoded and non-genetically encoded amino acids, chemically or biochemically modified or derived amino acids, and polypeptides having modified peptide backbones. The terms also include fusion proteins, including, but not limited to, fusion proteins with heterologous amino acid sequences, fusions containing leader sequences of heterologous and homologous origin (with or without an N-terminal methionine residue); and the like.

[0058] The definition of "percentage of amino acid sequence identity (%)" of a reference peptide sequence is the percentage of amino acid residues in a candidate sequence that are the same as those in a reference polypeptide sequence, after introducing gaps as necessary to achieve the maximum percentage sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percentage amino acid sequence identity can be achieved by several methods within the skill of the art, for example by publicly available computer software, such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm that achieves maximum comparison requirements for the full size of the sequences to be compared. However, for the purposes of the present invention, the percentage of amino acid sequence identity is obtained by the sequence comparison computer software ALIGN-2.

[0059] When comparing amino acid sequences by using ALIGN-2, the % amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B (or alternatively, a given amino acid sequence A that has or contains a certain % amino acid sequence identity to, with, or for a given amino acid sequence B) is calculated as follows: Fraction X / Y×100

[0060] where X is the number of amino acid residues that the sequence alignment program ALIGN-2 evaluates as identical and matching in its alignment of A and B, and Y is the total number of amino acid residues in B. It should be understood as follows: if the length of amino acid sequence A and the length of amino acid sequence B are not equal, then the % amino acid sequence identity of A to B will be different from the % amino acid sequence identity of B to A. Unless otherwise stated, all % amino acid sequence identity values ​​used in this text are as described in the previous paragraph and are obtained by the ALIGN-2 computer program.

[0061] As used herein, the term "treatment" refers to obtaining a desired pharmacological and / or physiological effect. The effect may be completely or partially preventing the onset or development of a disease or its symptoms, or partially or completely reducing the disease and / or its symptoms, and / or partially or completely curing the disease and / or its symptoms. It also includes: (a) preventing a disease from occurring in a subject, where the subject has the causative agent for the disease but has not been diagnosed with the disease; (b) inhibiting the disease or inhibiting its formation; and (c) attenuating a disease and / or its symptoms, i.e., causing a decrease or disappearance of the disease and / or its symptoms.

[0062] The terms "individual," "subject," and "patient" are used interchangeably herein and refer to mammals, including, but not limited to, murines (rats, mice), non-human primates, humans, dogs, cats, ungulates (e.g., horses, cows, sheep, pigs, goats), and the like.

[0063] A "therapeutically effective amount" or "effective amount" is an amount of a component of the plasminogen activation pathway or its related compound (e.g., plasminogen) that is capable of achieving said prevention and / or treatment of a disease when administered to a mammal or other subject and used to treat the disease. A "therapeutically effective amount" will vary according to the component of the plasminogen activation pathway or its related compound (e.g., plasminogen) used, the severity of the disease and / or symptoms, and the age, weight, etc., of the subject to be treated.

[0064] Preparation of the Plasminogen of the Invention For therapeutic use, plasminogen may be isolated and purified from nature or may be synthesized by standard chemical peptide synthesis techniques. When polypeptides are synthesized by chemical methods, the synthesis may be performed in liquid phase or solid phase. Solid phase polypeptide synthesis (SPPS), in which the C-terminal amino acid of the sequence is attached to an insoluble support and the remaining amino acids in the sequence are added in order, is suitable for the chemical synthesis of plasminogen. Various forms of SPPS, e.g., Fmoc and Boc, can be used to synthesize plasminogen. The techniques used for solid-phase synthesis are described in: Barany and Solid-Phase Peptide Synthesis; pages 3-284, The Peptides: Analysis, Synthesis, Biology. Volume 2: Special Methods in Peptide Synthesis, Part A., Merrifield, et al. J. Am. Chem. Soc., 85: 2149-2156 (1963); Stewart et al., Solid Phase Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, Ill. (1984); and Ganesan A. 2006 Mini Rev. Med Chem. 6: 3-10 and Camarero JA et al. 2005 Protein Pept Lett. 12: 723-8. Briefly, small insoluble porous beads are treated with functional units on which the peptide chain is built. After repeated coupling / deprotection cycles, the free N-terminal amine of the attached solid phase is coupled with a single N-protected amino acid unit, which is then deprotected to expose a new N-terminal amine for linking with another amino acid. The peptide remains immobilized on the solid phase and is then excised.

[0065] The plasminogen of the present invention is produced by standard recombinant methods. For example, a nucleic acid encoding plasminogen is inserted into an expression vector and operably linked to control sequences in the expression vector. Expression control sequences include, but are not limited to, a promoter (e.g., a naturally associated promoter or a heterologous promoter), a signal sequence, an enhancer element, and a transcription termination sequence. Control of expression can be a eukaryotic promoter system in a vector, which is transformed or transfected into a eukaryotic host cell (e.g., COS or CHO cells). Once the vector is introduced into a suitable host, the host is maintained under conditions suitable for high level expression of the nucleotide sequence and for collection and purification of the plasminogen.

[0066] Suitable expression vectors usually replicate in the host cell either free or as an integrated part of the host cell chromosomal DNA. Usually, expression vectors contain a selection marker (e.g., ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, or neomycin resistance) which is useful for detecting those cells which have been transformed in vitro with the desired DNA sequence.

[0067] Escherichia coli is an example of a prokaryotic host cell for cloning a polynucleotide encoding an antibody of interest. Other suitable microbial hosts include bacilli, such as Bacillus subtilis and other Enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, expression vectors can be generated, which usually contain expression control sequences (e.g., origins of replication) compatible with the host cell. There are also many known promoters, such as the lactose promoter system, the tryptophan (trp) promoter system, the β-lactamase promoter system, or the phage lambda-derived promoter system. Promoters generally control expression and may further include sequences such as ribosome binding sites to initiate transcription and translation when controlling gene sequences, as needed.

[0068] Other microorganisms, such as yeast, can also be used for expression. Yeast (e.g., Saccharomyces (S. cerevisiae) and Pichia are examples of suitable yeast host cells, in which suitable carriers include expression control sequences (e.g., promoters), origins of replication, termination sequences, etc., as necessary. Exemplary promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes for maltose and galactose utilization.

[0069] In addition to microorganisms, mammalian cells (e.g., mammalian cells cultured in in vitro cell culture) can also be used to express and produce the anti-Tau antibodies of the present invention (e.g., polynucleotides encoding such anti-Tau antibodies of interest). See, e.g., Winnacker, From Genes to Clones, VCH Publishers, NY, NY (1987). Suitable mammalian host cells include CHO cell lines, various Cos cell lines, HeLa cells, myeloma cell lines, and transformed B cells or hybridomas. Expression vectors for use in these cells can include expression control sequences, such as an origin of replication, a promoter, and an enhancer (Queen et al., Immunol. Rev. 89:49 (1986)), and required processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcription terminator sequences. Examples of suitable expression control sequences are promoters derived from rabbit immunoglobulin genes, SV40, adenovirus, bovine papilloma virus, cytomegalovirus, and the like. See Co et al., J. Immunol. 148:1149 (1992).

[0070] Once synthesized (chemically or recombinantly), the plasminogen according to the invention can be purified by standard procedures in the art, such as ammonium sulfate precipitation, affinity columns, column chromatography, high performance liquid chromatography (HPLC), gel electrophoresis, etc. The plasminogen is essentially pure, e.g., at least about 80% to 85% pure, at least about 85%-90% pure, at least about 90%-95% pure, or 98%-99% pure or even more pure, e.g., free of contaminants, such as cellular debris, large molecules other than the desired product, etc.

[0071] Drug combinations A component of the plasminogen activation pathway or related compound (e.g., plasminogen) of the desired purity is mixed with an optional pharmaceutical carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences, 16th ed., Osol, A. ed. (1980)) to form a lyophilized formulation or aqueous solution to obtain a therapeutic combination. Acceptable carriers, excipients, and stabilizers are non-toxic to subjects at the required dosages and concentrations, and further include buffers such as, for example, phosphates, citrates, and other organic acids. Antioxidants include ascorbyl methionine; preservatives (e.g., octadecyl dimethylbenzyl ammonium chloride; hexamethylenediamine chloride; benzalkonium chloride). chloride), benzethonium chloride; phenol, butanol or benzyl alcohol; alkyl parahydroxybenzoic acid esters, such as methyl or propyl parahydroxybenzoic acid ester; pyrocatechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol; low molecular weight polypeptides (those having less than about 10 residues); proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, aspartic acid, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates include glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, fucose or sorbitol; salt forming counterions, such as sodium; metal complexes (such as zinc-protein complexes); and / or non-ionic surfactants, such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG). A preferred lyophilized anti-VEGF antibody formulation is described in WO97 / 04801, incorporated herein by reference.

[0072] The combinations of the present invention may contain one or more active compounds as required for the particular condition requiring treatment, preferably those having complementary activities and no adverse effects on each other.

[0073] The plasminogen of the present invention can be encapsulated in microcapsules made, for example, by aggregation techniques or interfacial polymerization, can be incorporated, for example, into colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or can be incorporated into hydroxymethylcellulose or gel microcapsules and poly(methyl methacrylate) microcapsules in crude emulsions. These techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0074] The plasminogen activation pathway components or related compounds (e.g., plasminogen) of the present invention to be administered to the body must be sterile, which can be readily achieved by filtration through sterile filtration membranes, prior to or after lyophilization and recombination.

[0075] The plasminogen activation pathway components or related compounds (e.g., plasminogen) of the present invention can be prepared in sustained release formulations. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers having a defined shape and containing the glycoprotein, such as membranes or microcapsules. Examples of sustained release matrices include polyesters, aqueous gels (e.g., poly(2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater. Res., 15:167-277 (1981); Langer, Chem. Tech., 12:98-105 (1982)) or poly(vinyl alcohol), polylactide (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and ethyl-L-glutamic acid (Sidman, et al., Biopolymers 22:547 (1983)), non-degradable ethylene-vinyl acetate (Langer, et al., same source as above), or degradable lactic acid-hydroxyacetic acid copolymers, e.g., Lupron. Depot™ (injectable microspheres composed of lactic acid-hydroxyacetic acid copolymer and leuprolide acetate), and poly D-(-)-3-hydroxybutyrate. Polymers such as ethylene-ethyl acetate and lactic acid-hydroxyacetic acid can release molecules sustainedly for over 100 days, but some aqueous gels release proteins for a shorter period of time. Rational strategies can be designed to stabilize proteins depending on the mechanism involved. For example, if the aggregation mechanism is the exchange of sulfur disulfide bonds to form intermolecular SS bonds, stabilization can be achieved by modifying sulfhydryl residues, freeze-drying from acidic solutions, controlling humidity, using appropriate additives, and developing specific polymer matrix compositions.

[0076] Dosage and dosage Administration of the pharmaceutical compositions of the present invention can be achieved by different modes, such as nasal inhalation, aerosol inhalation, nasal or eye drops, intravenous, intraperitoneal, subcutaneous, intracranial, intrathecal, intraarterial (e.g., via the carotid artery), intramuscular, and intrarectal administration.

[0077] Preparations for use in parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solutions, Ringer's dextrose, dextrose and sodium chloride, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolytic replenishers, and the like. Preservatives and other additives may also be present, such as antimicrobial agents, antioxidants, chelating agents, inert gases, and the like.

[0078] A medical practitioner may determine a dosage regimen based on various clinical factors. For example, as is well known in the medical arts, the dosage regimen for any given patient is determined by several factors, including the patient's body type, body surface area, age, the specific compound being administered, sex, frequency and route of administration, overall health, and other drugs being administered at the same time. The dosage range of the plasminogen pharmaceutical composition of the present invention may be, for example, about 0.0001-2000 mg / kg of subject body weight daily, or about 0.001-500 mg / kg (e.g., 0.02 mg / kg, 0.25 mg / kg, 0.5 mg / kg, 0.75 mg / kg, 10 mg / kg, 50 mg / kg, etc.). For example, the dosage may be 1 mg / kg body weight or 50 mg / kg body weight or in the range of 1-50 mg / kg, or at least 1 mg / kg. Doses higher or lower than this illustrative range are also covered, particularly when considering the above factors. Intermediate doses within the above range are also within the scope of the present invention. Subjects may receive such doses daily, every other day, weekly, or according to any schedule determined by empirical analysis. An exemplary dose schedule is 0.01-100 mg / kg for several consecutive days. During the administration of the drug of the present invention, it is necessary to evaluate the therapeutic effect and safety in real time.

[0079] Product or drug kit One embodiment of the present invention is directed to an article of manufacture or drug kit comprising a component of the plasminogen activation pathway or its associated compound (e.g., plasminogen). The article of manufacture preferably comprises a container, a label or a protocol. Suitable containers are bottles, vials, syringes, etc. The containers can be made of a variety of materials, such as glass or plastic. The container contains a composition, the composition is effective to treat a disease or condition of the present invention, and has a sterile access (e.g., the container is an intravenous infusion pack or vial and includes a stopper that can be pierced by a hypodermic needle). At least one activator in the composition is a component of the plasminogen activation pathway or its associated compound (e.g., plasminogen). A label on or attached to the container describes the composition as being used to treat a disease or condition of the present invention. The article of manufacture further comprises a second container containing a pharmaceutical buffer, the pharmaceutical buffer including, for example, phosphate buffered saline, Ringer's solution, and glucose solution. It may further comprise other materials as may be required from a commercial and user perspective, i.e., other buffers, diluents, filters, needles, and syringes. The article of manufacture also includes a protocol with instructions for use, including, for example, instructing a user of the composition to administer to a patient a composition of a component of the plasminogen activation pathway or its related compound (e.g., plasminogen) and other medications associated with the treatment of a disease. EXAMPLES

[0080] The plasminogen used in the following examples (simply referred to as PLG) was derived from plasma of human donors and was purified according to the following publications: Kenneth C Robbins, Louis Summaria, David Elwyn et al. Further Studies on the Purification and Characterization of Human Plasminogen and Plasmin. Journal of Biological Chemistry, 1965, 240(1):541-550; Summaria L, Spitz F, Arzadon L et al. Isolation and characterization of the affinity chromatography forms of human Glu- and Lys-plasminogens and plasmins. J Biol Chem. 1976 Jun 25; 251(12):3693-9; HAGAN JJ, ABLONDI FB, DE RENZO EC. Purification and biochemical properties of human plasminogen. J Biol Chem. 1960 Based on the method described in Apr;235:1005-10, the process was optimized and purified from human donor plasma, where the plasminogen alone was greater than 98%. Example 1

[0081] Example 1 relates to the ability of plasminogen to promote the degradation of amyloid (Aβ) in a PBS buffer system. Eppendorf (EP) tubes were taken and the following groups were set up: (1) blank control group, (2) solvent control group, (3) plasminogen group, and (4) plasminogen + tPA group, with four tubes in each group. The blank control group was added with 43.3 μL saline, 16 μL plasminogen solution (0.575 mg / mL), 10 μL ultrapure water, and 30.7 μL PBS buffer (10 mM, pH 7.4, Thermo Fisher, 10010-031); the solvent control group was added with 43.3 μL Aβ40 (China Peptides Co., Ltd., 04010011521, 1.0 mg / mL), 16 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), 10 μL ultrapure water, and 30.7 μL PBS buffer; the plasminogen group was added with 43.3 μL Aβ40 (1.0 mg / mL), 16 μL plasminogen solution (0.575 mg / mL), 10 μL ultrapure water, and 30.7 μL PBS buffer were added; plasminogen + tPA group was added with 43.3 μL Aβ40 (1.0 mg / mL), 8 μL plasminogen solution (1.15 mg / mL), 8 μL tPA solution (1.0 mg / mL), 10 μL lysine solution (0.1 mM), and 30.7 μL PBS buffer. After incubation at 37 °C for 3 hours, the reaction was stopped by adding 100 μL of 0.1% trifluoroacetic acid solution, respectively. A 20% gel was prepared according to the instructions of the Tris-Tricine-SDS-PAGE gel preparation kit (Solarbio, P1320). Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 1 min, and then 20 μL of sample was taken and loaded. The electrophoresis conditions were run at 30 V for 1 h, followed by running to the bottom of the gel at 100 V. After electrophoresis, the gel was peeled off and placed in 1‰ Coomassie Brilliant Blue staining solution (1 g of Coomassie Brilliant Blue R250 dissolved in 1000 ml of a mixture of ethanol:glacial acetic acid:purified water in a volume ratio of 5:2:13) for 30 min, and then destained using a destaining solution (purified water:glacial acetic acid:absolute ethanol = 17:2:1 in volume). Gels were quantitatively scanned and photographed with an imaging densitometer. Accumulation of amyloid (Aβ) is an important factor in the formation of Alzheimer's disease. Aβ40 and Aβ42, which contain 40 and 42 residues, are deposited in the hippocampus and striatum of the brain to form senile plaques, which are the main cause of Alzheimer's disease. [1] Detection of Aβ40 and Aβ42 contents in cerebrospinal fluid is gradually becoming a physiological indicator of clinical Alzheimer's disease. As a result, the amount of Aβ40 in the solvent control group was defined as 100% and remained unchanged, in the plasminogen group, Aβ40 was partially degraded when only plasminogen was added, and in the plasminogen + tPA group, when plasminogen and tPA were added, the in vitro degradation of Aβ40 was obvious, with a significant difference compared with the solvent control group (** represents P < 0.01) (Figure 1). This indicates that plasminogen can promote the degradation of Aβ40 in the PBS buffer system. Example 2

[0082] Example 2 relates to the ability of plasminogen to promote the degradation of amyloid (Aβ) in rabbit cerebrospinal fluid. Eppendorf (EP) tubes were taken and the following groups were set up: (1) blank control group, (2) solvent control group, and (3) plasminogen group, with four tubes in each group. The blank control group was added with 43.3 μL saline, 16 μL plasminogen solution (0.575 mg / mL), and 40.7 μL rabbit cerebrospinal fluid; the solvent control group was added with 43.3 μL Aβ40 (ChinaPeptides Co., Ltd., 04010011521, 1.0 mg / mL), 16 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 40.7 μL rabbit cerebrospinal fluid; the plasminogen group was added with 43.3 μL Aβ40 (1.0 mg / mL), 16 μL plasminogen solution (0.575 mg / mL), and 40.7 μL rabbit cerebrospinal fluid. After that, the mixture was incubated at 37° C. for 3 hours, and then 100 μL of 0.1% trifluoroacetic acid solution was added to each mixture to stop the reaction. A 20% gel was prepared according to the instructions of the Tris-Tricine-SDS-PAGE gel preparation kit (Solarbio, P1320). Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 1 min, and then 20 μL of sample was taken and loaded. The electrophoresis conditions were run at 30 V for 1 h, followed by running at 100 V to the bottom of the gel. After electrophoresis, the gel was peeled off and placed in 1‰ Coomassie Brilliant Blue staining solution (1 g of Coomassie Brilliant Blue R250 was dissolved in 1000 ml of a mixture of ethanol:glacial acetic acid:purified water in a volume ratio of 5:2:13) for 30 min, and then destained using a destaining solution (purified water:glacial acetic acid:absolute ethanol = 17:2:1 in volume). Gels were quantitatively scanned and photographed with an imaging densitometer. As a result, the amount of Aβ40 in the solvent control group was defined as 100% and remained unchanged, while in the plasminogen group, Aβ40 was partially degraded when only plasminogen was added, being degraded to 74.81% (Figure 2). This indicates that plasminogen can promote the degradation of Aβ40 in the cerebrospinal fluid of rabbits. Example 3

[0083] Example 3 relates to the fact that plasminogen promotes the degradation of human amyloid Aβ40 in brain homogenates of Alzheimer's disease models and normal mice. Four 11-week-old B6SJLTg(APPSwFlLon, PSEN1*M146L*L286V)6799Vas / Mmjax(FAD) (Stock No.: 034840) (abbreviated as FAD) and C57BL / 6 (normal) mice were selected and sacrificed to collect whole brain tissues, which were then weighed and placed in Eppendorf (EP) tubes, and 1×PBS (Thermo Fisher, pH 7.4; 10010-031) was added at 150 mg tissue / mL PBS, homogenized at 4°C (1 min / time, 3-4 times). After homogenization, the homogenized tissues were centrifuged at 4°C (12000 rpm, 15 min), and the supernatant brain homogenate was transferred to a new EP tube. Eppendorf (EP) tubes were taken and five parallels were set up for each group: (1) blank control group, (2) solvent control group, and (3) plasminogen group. The blank control group was added with 21.5 μL saline, 4.6 μL plasminogen solution (2 mg / mL), and 23.9 μL mouse brain homogenate; the solvent control group was added with 21.5 μL Aβ40 (ChinaPeptides Co., Ltd., 04010011521, 1.0 mg / mL), 4.6 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL mouse brain homogenate; the plasminogen group was added with 21.5 mL Aβ40 (1.0 mg / mL), 4.6 μL plasminogen solution (2 mg / mL), and 23.9 μL mouse brain homogenate. After the samples were added to each group, the mixture was incubated at 37° C. for 6 hours, and then 50 μL of 0.1% trifluoroacetic acid solution was added to each group to stop the reaction. A 20% gel was prepared according to the instructions of the Tris-Tricine-SDS-PAGE gel preparation kit (Solarbio, P1320). Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 1 min, and then 20 μL of sample was taken and loaded. The electrophoresis conditions were run at 30 V for 1 h, followed by running at 100 V to the bottom of the gel. After electrophoresis, the gel was peeled off and placed in 1‰ Coomassie Brilliant Blue staining solution (1 g of Coomassie Brilliant Blue R250 was dissolved in 1000 ml of a mixture of ethanol:glacial acetic acid:purified water in a volume ratio of 5:2:13) for 30 min, and then destained using a destaining solution (purified water:glacial acetic acid:absolute ethanol = 17:2:1 in volume). The gels were photographed and quantitatively scanned with a biomolecular imager. As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of human amyloid Aβ40 in the plasminogen group was significantly lower than that in the solvent control group, and the difference was highly significant (*** indicates P<0.001=); in the brain homogenates of normal mice, the amount of amyloid Aβ40 in the plasminogen group was significantly lower than that in the solvent control group, and the difference was highly significant (P=0.001) (Figure 3). This indicates that plasminogen can effectively promote the degradation of human amyloid Aβ40 in the brain homogenates of Alzheimer's disease model and normal mice. Example 4

[0084] Example 4 relates to the promotion of degradation of human amyloid Aβ42 in Alzheimer's disease models and normal mouse brain homogenates. Four 11-week-old B6SJLTg(APPSwFlLon, PSEN1*M146L*L286V)6799Vas / Mmjax(FAD) (Stock number: 034840) (abbreviated as FAD) and C57BL / 6 (normal) mice were selected and sacrificed to collect whole brain tissues, which were then weighed and placed in Eppendorf (EP) tubes, and 1×PBS (Thermo Fisher, pH 7.4; 10010-031) was added at 150 mg tissue / mL PBS, homogenized at 4°C (1 min / time, 3-4 times). After homogenization, the homogenized tissues were centrifuged at 4°C (12000 rpm, 15 min), and the supernatant brain homogenate was transferred to a new EP tube. Eppendorf (EP) tubes were taken and five parallels were set up for each group: (1) blank control group, (2) solvent control group, and (3) plasminogen group. The blank control group was added with 21.5 μL saline, 4.6 μL plasminogen solution (2 mg / mL), and 23.9 μL mouse brain homogenate; the solvent control group was added with 21.5 μL Aβ42 (ChinaPeptides Co., Ltd., 04010011526, 1.0 mg / mL), 4.6 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL mouse brain homogenate; the plasminogen group was added with 21.5 mL Aβ42 (1.0 mg / mL), 4.6 μL plasminogen solution (2 mg / mL), and 23.9 μL mouse brain homogenate. After the samples were added to each group, the mixture was incubated at 37° C. for 6 hours, and then 50 μL of 0.1% trifluoroacetic acid solution was added to each group to stop the reaction. A 20% gel was prepared according to the instructions of the Tris-Tricine-SDS-PAGE gel preparation kit (Solarbio, P1320). Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 1 min, and then 20 μL of sample was taken and loaded. The electrophoresis conditions were run at 30 V for 1 h, followed by running at 100 V to the bottom of the gel. After electrophoresis, the gel was peeled off and placed in 1‰ Coomassie Brilliant Blue staining solution (1 g of Coomassie Brilliant Blue R250 was dissolved in 1000 ml of a mixture of ethanol:glacial acetic acid:purified water in a volume ratio of 5:2:13) for 30 min, and then destained using a destaining solution (purified water:glacial acetic acid:absolute ethanol = 17:2:1 in volume). The gels were photographed and quantitatively scanned with a biomolecular imager. As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of amyloid Aβ42 in the plasminogen group was lower than that in the solvent control group, and the amounts of polymers a, b, and c were all significantly lower than those in the solvent group, and the difference was highly significant (* indicates P<0.05, *** indicates P<0.001=); in the brain homogenates of normal mice, the amount of amyloid Aβ42 in the plasminogen group was significantly lower than that in the solvent control group, and the difference was highly significant (*** indicates P<0.001=), and the amounts of polymers a, b, and c were all lower than those in the solvent group, and the difference was highly significant (*** indicates P<0.001= (Figure 4)). This indicates that plasminogen can effectively promote the degradation of human amyloid Aβ42 and its polymers in the brain homogenates of FAD and normal mice. Example 5

[0085] Example 5 relates to the promotion of memory function recovery in Alzheimer's disease model mice by plasminogen. B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax (abbreviated as FAD) (purchased from Jackson lab, catalog number: 034840) mice are a transgenic model mouse commonly used in Alzheimer's disease research. Twelve 12-week-old FAD female mice were taken and randomly divided into two groups, vehicle group and treatment group, according to the weight results, with six mice in each group, and six SJLB6 (stock number: 10012) female mice were selected as normal control group. The mice in the treatment group were administered plasminogen via tail vein injection at 1ml / 0.1ml / mouse / day, and the mice in the vehicle group were administered the same amount of vehicle (4% arginine + 2% glycine solution) via intravenous injection for 5 consecutive days. The mice in the normal control group were not administered. The first day of administration was designated as day 1, and the Y-maze spontaneous alternation behavior experiment was conducted on day 6. The Y-maze consists of three identical arms. There is a food supply device at the end of each arm, and the spatial memory ability of experimental animals is reflected by analyzing the parameters of the animal's food acquisition strategy, i.e., the number of times, time, correct number, incorrect number, and route to enter each arm, which is now commonly used to evaluate learning and memory function. This experiment utilizes the exploration characteristics of rodents in a new environment. The animal must rely on previous memory to select the correct arm entry. This can effectively evaluate the animal's spatial working memory ability. During the experiment, the animal was placed at the end of one arm and allowed to freely explore for a few minutes, and after a certain period of time, the animal was placed in the maze again for formal testing. The order and total number of times the animal entered each arm were recorded, and if the animal entered different arms (e.g., 1, 2, 3 or 1, 3, 2) consecutively, it was recorded as one correct alternation behavior. The animal was placed at the end of one arm, and the order in which the animal entered each arm was recorded for 8 minutes. The maximum number of alternations is the sum of the number of arm entries minus 2, and the percentage is calculated as actual number of alternations / maximum number of alternations x 100%, and the final value given includes the actual number of alternations, the maximum number of alternations, the percentage of both, the total distance traveled by the animal, and the total number of arm entries. [2] . Alzheimer's disease (AD) is an insidious, progressive neurodegenerative disorder characterized by cognitive impairment, neurodegeneration, β-amyloid deposition, neurofibrillary tangles, and neuroinflammation. [3] FAD transgenic mice are a commonly used model animal for the development of AD therapeutics. Spontaneous alternation rate The spontaneous alternation rate is the ratio of the actual alternation to the maximum alternation × 100%. As a result, compared with the normal control mice, the spontaneous alternation rate of the mice in the vehicle group was significantly increased, and the spontaneous alternation rate of the mice in the treatment group was significantly lower than that of the vehicle control group, with statistical differences being significant (* indicates P < 0.05), and close to that of the normal control mice (Figure 5). Total arm entries The total number of arm entries is the total number of times that the mouse entered the arm within a specified time. As a result, compared with the normal control group, the total number of arm entries of the mice in the vehicle group was significantly decreased, and the total number of arm entries of the mice in the treatment group was significantly higher than that of the mice in the vehicle control group, with statistical differences being significant (* indicates P<0.05), and close to that of the normal control mice (Figure 6). Total movement distance The total distance traveled refers to the total length of the mouse's movement trajectory within a specified time. As a result, compared with the normal control mice, the total distance traveled by the mice in the solvent group was significantly decreased, and the total distance traveled by the mice in the treatment group was significantly longer than that of the mice in the solvent control group, with statistical differences being significant (* indicates P<0.05), and closer to the normal control mice (Figure 7). The above results indicate that plasminogen can promote the recovery of spontaneous alternation behavior and memory recovery in Alzheimer's disease model mice. Example 6

[0086] Example 6 relates to the effect of plasminogen on reducing Aβ42 deposition in the cerebral cortex of Alzheimer's disease model mice. Twenty 8-week-old C57 male mice were taken and weighed before modeling. After excluding abnormal mice according to body weight, all mice were randomly divided into two groups, a vehicle group and a treatment group, with 10 mice in each group. All mice were anesthetized and located in the granulocyte layer of the hippocampus according to the mouse stereotaxic atlas (located according to the coordinates of the bregma point: AP-2.0mm, ML±1.5mm, DV2.0mm), and slowly microinjected into both sides of each mouse, with an injection speed of 0.5μL / min and an injection volume of 3μL, to create the Alzheimer's model. [3]To construct the model group, mice were injected with Aβ1-42 oligomer solution, and mice in the model control group were injected with PBS solution. Preparation of Aβ1-42 oligomer solution (10 μM): Take β-amyloid (1-42) (ChinaPeptides Co., Ltd., Shanghai Qianyao Biological Technology Co., Ltd., 04010011521), add cold hexafluoroisopropanol to make the concentration 1 mg / ml, leave at room temperature for 3 days, then dispense into 45 μL / tube, i.e. 10 nmol / mL, leave in a fume hood overnight, dry in a 25 °C dry oven for 1 hour, and then store at -80 °C. When used, add 10 μl of dimethyl sulfoxide solution to each tube to dissolve, and when injected, add 990 μL of sterile PBS solution, and leave at 4 °C for 24 hours before use. 21 days after the brain localized injection, administration was started to the mice in the vehicle group and the treatment group, which was designated as the first day. Plasminogen was administered to the mice in the treatment group at 1 mg / 0.1 ml / mouse / day by tail vein injection, and the mice in the vehicle group were administered the solvent (4% arginine + 2% glycine solution) at 0.1 ml / mouse / day by tail vein injection for 28 consecutive days. On the 29th day, the mice were sacrificed, and the brains were collected and fixed in 10% formaldehyde for 24-48 hours. The fixed brain tissue was dehydrated in an alcohol gradient, permeabilized with xylene, and then embedded in paraffin. The substantia nigra was located, the thickness of the sections was 4 μm, and the sections were deparaffinized, rehydrated, and washed once with water. The tissue was circled with a PAP marker, incubated in 3% hydrogen peroxide for 15 minutes, and washed twice with 0.01M PBS, for 5 minutes each time. Blocking was performed with 5% normal goat serum (Vector Laboratories, Inc., USA) for 30 minutes, and when the time was up, the goat serum was discarded. Rabbit anti-mouse Aβ42 antibody (Abcam, ab201060) was dropped and incubated overnight at 4°C, and washed twice with 0.01M PBS, each time for 5 minutes. Goat anti-rabbit IgG (HRP) antibody (Abcam) secondary antibody was incubated at room temperature for 1 hour, washed twice with 0.01M PBS, each time for 5 minutes. Coloring was performed with a DAB kit (Vector laboratories, Inc., USA), and after washing three times with water, counterstaining with hematoxylin for 30 seconds was performed, and rinsing was performed with running water for 5 minutes.The sections were dehydrated in a graded alcohol solution, cleared in xylene, and embedded in neutral rubber, and the sections were observed under an optical microscope at 200x magnification. The neurotoxic effects of β-amyloid (amyloid β protein, Aβ) play a major role in the progression of Alzheimer's disease. [4] . As a result, the deposition level of Aβ42 in the cerebral cortex of mice in the vehicle group (Figure 8A) was significantly higher than that in the treatment group (Figure 8B), and the statistical difference in the quantitative analysis results of optical density was significant (* indicates P<0.05) (Figure 8C). This suggests that plasminogen can reduce the deposition of Aβ42 in the cerebral cortex of Alzheimer's disease model mice. Example 7

[0087] Example 7 relates to the effect of plasminogen in reducing Aβ42 levels in brain tissue of Alzheimer's disease model mice. B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax mice (catalog number: 034840, purchased from Jackson Laboratory) and C57BL / 6J mice were backcrossed once to breed offspring (referred to as B6-F1-FAD). Eighteen 16-17 week-old female B6-F1-FAD mice and nine 9 week-old female C57BL / 6J mice were taken. B6-F1-FAD were randomly divided into two groups, a vehicle group and a treatment group, with nine mice in each group, according to their body weight and the results of the Y-maze test. Nine C57BL / 6J mice were used as a blank control group. After grouping was completed, the mice in the blank control group and the mice in the vehicle group were administered vehicle (4% arginine + 2% glycine solution) via tail vein injection, and the injection volume for each mouse was 5ml / kg. Plasminogen was administered to the mice in the treatment group via tail vein injection, and each mouse was injected with 50 mg / kg of plasminogen for 8 consecutive days. Five days after administration, 7 mice, 7 mice, and 6 mice were randomly selected from the blank group, vehicle group, and treatment group, respectively, and sacrificed. Brain tissues were collected and homogenized at 4℃, and the supernatant homogenate was used to detect total protein concentration by BCA method and Western blot detection. A 16.5% gel was prepared according to the instructions of the Tris-Tricine-SDS-PAGE gel preparation kit (Solarbio, P1320). Each group of samples was mixed uniformly with 4× loading buffer (TaKaRa, e2139) at a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 100 μg of total protein was collected and loaded. The electrophoresis conditions were run at 30 V for 1.5 h, followed by running to the bottom of the gel at 100 V. After electrophoresis, the gel was peeled off and transferred to a PVDF membrane (GE, A29433753), and the electrophoresis conditions were 15 V for 2.5 h. The transferred PVDF membrane was immersed in a blocking solution (5% skim milk solution), blocked overnight in a refrigerator at 4 °C, washed four times with TBST (0.01 M Tris-NaCl, pH 7.6 buffer), added rabbit anti-mouse Aβ42 antibody (Abcam, ab201060) and incubated at room temperature for 2 hours, washed four times with TBST, added goat anti-rabbit IgG (HRP) antibody (Abcam, ab6721) secondary antibody, incubated at room temperature for 1 hour, washed four times with TBST, placed on a clean imaging plate, added Immobilon Western HRP Substrate (MILLIPORE, WBKLS0100) for color development, photographed with a biomolecular imager, and quantitatively analyzed with Image J. As a result, there was a certain level of Aβ42 protein in the brain homogenate of the mice in the blank control group, and the level of Aβ42 in the brain tissue of the mice in the solvent group was significantly higher than that of the mice in the treatment group, with a statistical P value of 0.09 (Figure 9). This indicates that plasminogen can reduce the level of Aβ42 in the brain tissue of Alzheimer's disease model mice. Example 8

[0088] Example 8 relates to the fact that plasminogen promotes the degradation of Tau protein in brain homogenates of normal mice. Four C57BL / 6J male mice aged 11–12 weeks and weighing 18–25 g were selected and sacrificed to collect whole brain tissue, which was then weighed and added with 1× PBS (Thermo Fisher, pH 7.4; 10010-031) at 150 mg tissue / mL PBS, homogenized at 4°C (1 min / time, 3–4 times), and centrifuged at 4°C (12000 rpm, 20 min) after homogenization, and the supernatant brain homogenate was transferred to a new EP tube. Take Eppendorf (EP) tubes and set up five parallels for each group: (1) blank group, (2) blank control group, (3) solvent control group, and (4) plasminogen group. The blank group was added with 21.5 μL saline, 4.6 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL mouse brain homogenate; the blank control group was added with 21.5 μL saline, 4.6 μL plasminogen solution (0.5 mg / mL), and 23.9 μL mouse brain homogenate; the solvent control group was added with 21.5 μL Tau protein solution (Nanjing GenScript Biotechnology Co., Ltd., custom-expressed human Tau To the plasminogen group, 21.5 μL of Tau protein solution (1.0 mg / mL), 4.6 μL of plasminogen solution (0.5 mg / mL), and 23.9 μL of mouse brain homogenate were added; to the plasminogen group, 21.5 μL of Tau protein solution (1.0 mg / mL), 4.6 μL of plasminogen solution (0.5 mg / mL), and 23.9 μL of mouse brain homogenate were added. After adding the samples to each group, the reaction was stopped by adding 50 μL of 0.1% trifluoroacetic acid solution, respectively, after incubation at 37 °C for 6 hours. A 10% gel was prepared according to the instructions of the SDS-PAGE gel preparation kit. Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 20 μL of sample was taken for loading. The electrophoresis conditions were run at 30 V for 45 min, followed by 100 V to the bottom of the gel. After electrophoresis, the gel was peeled off and transferred to an activated PVDF membrane (GE, A29433753), and the electrophoresis conditions were 15 V for 2.5 h. The transferred PVDF membrane was immersed in a blocking solution (5% skim milk solution), blocked overnight in a refrigerator at 4 °C, washed four times with TBST (0.01 M Tris-NaCl, pH 7.6 buffer), added rabbit Tau protein antibody (Abcam, ab151559) and incubated at room temperature for 2 hours, washed four times with TBST, added goat anti-rabbit IgG (HRP) antibody (Abcam, ab6721) secondary antibody, incubated at room temperature for 1 hour, washed four times with TBST, placed on a clean imaging plate, added Immobilon Western HRP Substrate (MILLIPORE, WBKLS0100) for color development, photographed with a biomolecular imager, and quantitatively analyzed with Image J. Tau protein is the most abundant microtubule-associated protein. Tau protein is a phosphate-containing protein, and Tau protein molecules in normal mature brains contain 2-3 phosphate groups. Tau protein in the brains of patients with Alzheimer's disease (senile dementia) is abnormally hyperphosphorylated, and each molecule of Tau protein may contain 5-9 phosphate groups, which may cause loss of normal biological function. [5] . As a result, in the brain homogenates of normal mice, the amount of Tau protein in the plasminogen group was significantly lower than that in the solvent control group, and the difference was significant (* represents P<005, ** represents P<0.01, *** represents P<0.001) (Figure 10). This suggests that plasminogen can promote the degradation of Tau protein in the brain homogenates of normal mice. Example 9

[0089] Example 9 relates to the fact that plasminogen promotes the degradation of Tau protein in brain homogenates from Alzheimer's disease mice. Four 11-week-old B6SJLTg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax(FAD) (Stock number: 034840) (abbreviated as FAD) mice were selected and sacrificed to collect whole brain tissue, which was then weighed and brain homogenates were prepared as in Example 8 and placed in EP tubes. Eppendorf (EP) tubes were taken and five parallels were set up for each group: (1) blank group, (2) blank control group, (3) solvent control group, and (4) plasminogen group. The blank group was added with 21.5 μL saline, 4.6 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL mouse brain homogenate; the blank control group was added with 21.5 μL saline, 4.6 μL plasminogen solution (0.5 mg / mL), and 23.9 μL mouse brain homogenate; the solvent control group was added with 21.5 μL Tau (Nanjing GenScript Biotechnology Co., Ltd., custom-expressed human Tau To the plasminogen group, 21.5 μL of Tau (1.0 mg / mL), 4.6 μL of plasminogen solution (0.5 mg / mL), and 23.9 μL of mouse brain homogenate were added; to the plasminogen group, 21.5 μL of Tau (1.0 mg / mL), 4.6 μL of plasminogen solution (0.5 mg / mL), and 23.9 μL of mouse brain homogenate were added. After adding the samples to each group, the samples were incubated at 37 °C for 6 hours, and then 50 μL of 0.1% trifluoroacetic acid solution was added to each group to stop the reaction. A 10% gel was prepared according to the instructions of the SDS-PAGE gel preparation kit. Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 20 μL of sample was taken for loading. The electrophoresis conditions were run at 30 V for 45 min, followed by 100 V to the bottom of the gel. After electrophoresis, the gel was peeled off and transferred to an activated PVDF membrane (GE, A29433753), and the electrophoresis conditions were 15 V for 2.5 h. The transferred PVDF membrane was immersed in a blocking solution (5% skim milk solution), blocked overnight in a refrigerator at 4 °C, washed four times with TBST (0.01 M Tris-NaCl, pH 7.6 buffer), added rabbit Tau protein antibody (Abcam, ab151559) and incubated at room temperature for 2 hours, washed four times with TBST, added goat anti-rabbit IgG (HRP) antibody (Abcam, ab6721) secondary antibody, incubated at room temperature for 1 hour, washed four times with TBST, placed on a clean imaging plate, added Immobilon Western HRP Substrate (MILLIPORE, WBKLS0100) for color development, photographed with a biomolecular imager, and quantitatively analyzed with Image J. As a result, in the brain homogenates of Alzheimer's disease mice, the amount of Tau protein in the plasminogen group was significantly lower than that in the solvent control group, and the difference was statistically significant (* indicates P<005, ** indicates P<0.01) (Figure 11). This suggests that plasminogen can promote the degradation of Tau protein in the brain homogenates of Alzheimer's disease mice. Example 10

[0090] Example 10 relates to the effect of plasminogen in reducing Tau protein levels in brain tissue of Alzheimer's disease model mice. B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax mice (catalog number: 034840, purchased from Jackson Laboratory) and C57BL / 6J mice were backcrossed three times to breed offspring (referred to as B6-F3-FAD). Eighteen female B6-F3-FAD mice aged 20-25 weeks and nine female C57BL / 6J mice aged 9 weeks were taken. B6-F3-FAD were randomly divided into two groups, a vehicle group and a treatment group, with nine mice in each group, according to their body weight and the results of the Y-maze test. Nine C57BL / 6J mice were used as a blank control group. After grouping was completed, the mice in the blank control group and the mice in the vehicle group were administered vehicle (4% arginine + 2% glycine solution) via tail vein injection, and the injection volume for each mouse was 5ml / kg. Plasminogen was administered to the mice in the treatment group via tail vein injection, with each mouse receiving plasminogen at a dose of 50 mg / kg for 28 consecutive days. Seven days after administration, mice were randomly selected from each group and sacrificed, and their brain tissues were collected and homogenized at 4°C. The homogenate supernatant was used to detect total protein concentration by BCA method and Western blot detection. A 10% gel was prepared according to the instructions of the SDS-PAGE gel preparation kit (Solarbio, P1320). Each group of samples was mixed uniformly with 4× loading buffer (TaKaRa, e2139) at a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 100 μg of total protein was collected and loaded. The electrophoresis conditions were run at 30 V for 1.5 h, followed by running to the bottom of the gel at 100 V. After electrophoresis, the gel was peeled off and transferred to a PVDF membrane (GE, A29433753), and the electrophoresis conditions were 15 V for 2.5 h. The transferred PVDF membrane was immersed in a blocking solution (5% skim milk solution), blocked overnight in a refrigerator at 4 °C, washed four times with TBST (0.01 M Tris-NaCl, pH 7.6 buffer), added rabbit anti-mouse Tau antibody (Abcam, ab151559) and incubated at room temperature for 2 hours, washed four times with TBST, added goat anti-rabbit IgG (HRP) antibody (Abcam, ab6721) secondary antibody, incubated at room temperature for 1 hour, washed four times with TBST, placed on a clean imaging plate, added Immobilon Western HRP Substrate (MILLIPORE, WBKLS0100) for color development, photographed with a biomolecular imager, and quantitatively analyzed with Image J. The results showed that there were certain levels of Tau proteins of different molecular weights in the brain homogenates of mice in the blank control group, and the levels of Tau proteins of each molecular weight and total Tau protein in the brain tissues of mice in the treatment group were significantly lower than those of mice in the vehicle group, and the statistical analysis P values ​​of 35kd, 35-40kd, 40kd, and 54kd molecular weight Tau protein levels and total Tau protein levels of the two groups were 0.174, 0.0406, 0.052, 0.067, and 0.055, respectively (Figure 12). This indicates that plasminogen can promote the degradation of Tau protein in the brain tissues of Alzheimer's model mice. Example 11

[0091] Example 11 relates to the fact that plasminogen promotes the cleavage of Pro-BDNF in brain homogenates of Alzheimer's disease model mice. Four 11-week-old B6SJLTg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax(FAD) (Stock number: 034840) (abbreviated as FAD) mice were selected and sacrificed to collect whole brain tissue, and brain homogenates were prepared as described above and placed in EP tubes. Take Eppendorf (EP) tubes and set up five parallels for each group: (1) blank group, (2) blank control group, (3) solvent control group, and (4) treatment group. The blank group was added with 21.5 μL of saline, 4.6 μL of solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL of mouse brain homogenate; the blank control group was added with 21.5 μL of saline, 4.6 μL of plasminogen solution (2 mg / mL), and 23.9 μL of mouse brain homogenate; the solvent control group was added with 21.5 μL of Pro-BDNF (Nanjing GenScript Biotechnology Co., Ltd., custom-expressed, UniProtKB-P23560, 1.0 mg / mL), 4.6 μL of solvent solution (citric acid-sodium citrate solution), and 23.9 μL of mouse brain homogenate were added to the plasminogen group; 21.5 mL of Pro-BDNF (1.0 mg / mL), 4.6 μL of plasminogen solution (2 mg / mL), and 23.9 μL of mouse brain homogenate were added to the plasminogen group. After adding the samples to each group, they were incubated at 37 °C for 6 hours, and then 50 μL of 0.1% trifluoroacetic acid solution was added to each group to stop the reaction. A 12% gel was prepared according to the instructions of the SDS-PAGE gel preparation kit. Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 20 μL of sample was taken and loaded. Electrophoresis conditions were run at 30 V for 45 min, followed by running to the bottom of the gel at 100 V. After electrophoresis, the gel was peeled off and placed in 1‰ Coomassie Brilliant Blue staining solution (1 g of Coomassie Brilliant Blue R250 was dissolved in 1000 ml of a mixture of ethanol:glacial acetic acid:purified water in a volume ratio of 5:2:13) for 30 min, and then destained cleanly using a destaining solution (purified water:glacial acetic acid:absolute ethanol = 17:2:1 volume ratio). The gel was photographed with a biomolecular imager and quantitatively scanned and analyzed. Brain-derived neurotrophic factor (BDNF) is a basic protein with a molecular weight of 12.3 kD, consisting of 119 amino acid residues and containing three pairs of disulfide bonds. It exists in a dimerized form in vivo and is synthesized in the form of a BDNF precursor, which can be cleaved by enzymatic hydrolysis to form mature BDNF. It has been reported in the literature that Pro-BDNF has the opposite effect to that of the cleaved mature BDNF. Pro-BDNF promotes neuronal apoptosis and reduces synaptic plasticity. [6] Mature BDNF and its receptors are widely distributed in the central nervous system and play an important role in the survival, differentiation, growth and development of neurons during the development of the central nervous system. They can prevent neurons from being damaged and dying, improve the pathological condition of neurons, and promote biological effects such as the regeneration and differentiation of damaged neurons, and are necessary for the survival and normal physiological functions of neurons in the mature central nervous system and peripheral nervous system. [7] . As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of Pro-BDNF in the plasminogen-administered group was significantly lower than that in the solvent control group, and the difference was highly significant (* indicates P<0.05, *** indicates P<0.001) (Figure 13). This suggests that plasminogen can promote the cleavage of Pro-BDNF in the brain homogenates of Alzheimer's disease model mice. Example 12

[0092] Example 12 relates to the fact that plasminogen promotes the cleavage of Pro-BDNF and the formation of mature BDNF in brain homogenates from Alzheimer's disease model mice. Four 11-week-old B6SJLTg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax(FAD) (Stock number: 034840) (abbreviated as FAD) mice were selected and sacrificed to collect whole brain tissue, and brain homogenates were prepared as described above and placed in EP tubes. Take Eppendorf (EP) tubes and set up five parallels for each group: (1) blank group, (2) blank control group, (3) solvent control group, and (4) treatment group. The blank group was added with 21.5 μL of saline, 4.6 μL of solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL of mouse brain homogenate; the blank control group was added with 21.5 μL of saline, 4.6 μL of plasminogen solution (2 mg / mL), and 23.9 μL of mouse brain homogenate; the solvent control group was added with 21.5 μL of Pro-BDNF (Nanjing GenScript Biotechnology Co., Ltd., custom-expressed, UniProtKB-P23560, 1.0 mg / mL), 4.6 μL of solvent solution (citric acid-sodium citrate solution), and 23.9 μL of mouse brain homogenate were added to the plasminogen group; 21.5 mL of Pro-BDNF (1.0 mg / mL), 4.6 μL of plasminogen solution (2 mg / mL), and 23.9 μL of mouse brain homogenate were added to the plasminogen group. After adding the samples to each group, they were incubated at 37 °C for 6 hours, and then 50 μL of 0.1% trifluoroacetic acid solution was added to each group to stop the reaction. A 12% gel was prepared according to the instructions of the SDS-PAGE gel preparation kit. Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 20 μL of sample was taken for loading. The electrophoresis conditions were run at 30 V for 45 min, followed by 100 V to the bottom of the gel. After electrophoresis, the gel was peeled off and transferred to a PVDF membrane (GE, A29433753), and the electrophoresis conditions were 15 V for 2.5 h. The transferred PVDF membrane was immersed in a blocking solution (5% skim milk solution), blocked overnight in a refrigerator at 4 °C, washed four times with TBST (0.01 M Tris-NaCl, pH 7.6 buffer), added rabbit anti-human BDNF antibody (Boster Biological Technology, PB9075), incubated at room temperature for 3 hours, washed four times with TBST, added goat anti-rabbit IgG (HRP) antibody (Abcam, ab6721) secondary antibody, incubated at room temperature for 1 hour, washed four times with TBST, placed on a clean imaging plate, added Immobilon Western HRP Substrate (MILLIPORE, WBKLS0100) for color development, photographed with a biomolecular imager, and quantitatively analyzed the band optical density with Image J. As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of Pro-BDNF in the plasminogen-administered group was significantly lower than that in the solvent control group, and the difference was highly significant (** indicates P<0.01, *** indicates P<0.001); the amount of BDNF in the plasminogen-administered group was significantly higher than that in the solvent control group, and the difference was highly significant (Figure 14). This suggests that plasminogen can promote the cleavage of Pro-BDNF and the formation of mature BDNF in the brain homogenates of Alzheimer's disease model mice. Example 13

[0093] Example 13 relates to the fact that plasminogen promotes the expression of BDNF in the hippocampus of Alzheimer's disease model mice. Twenty-three 24-week-old C57 male mice were taken and weighed before modeling. After excluding abnormal mice according to body weight, all mice were randomly divided into two groups, 7 in the blank control group and 16 in the model group. All mice were anesthetized and modeled as in Example 6. [3] A model was constructed. 28 days after the brain localized injection, all mice were subjected to weight and Y-maze tests, and abnormal mice in the blank control group and model group were eliminated according to the results of the tests, and the model group mice were randomly divided into two groups, six in the solvent group, seven in the treatment group, and six in the blank control group. Administration was started to the mice in the solvent group and treatment group, which was the first day, and plasminogen was administered to the mice in the treatment group at 1 mg / 0.1 ml / mouse / day by tail vein injection, and the mice in the solvent group were administered with solvent (4% arginine + 2% glycine solution) at 0.1 ml / mouse / day by tail vein injection for 28 consecutive days. No administration was given to the blank control group mice. On the 29th day, the mice were sacrificed, and the brains were collected and fixed in 10% formaldehyde for 24 to 48 hours. The fixed brain tissue was dehydrated in an alcohol gradient, permeabilized with xylene, and then embedded in paraffin. The substantia nigra was located, the section thickness was 4 μm, the sections were deparaffinized and rehydrated, and then washed once with water. The tissue was circled with a PAP marker, incubated with 3% hydrogen peroxide for 15 min, washed twice with 0.01 M PBS, 5 min each time. Blocked with 5% normal goat serum (Vector Laboratories, Inc., USA) for 30 min, discarded the goat serum when the time was up, dropped rabbit anti-mouse BDNF antibody (BosterBio, PB9075) and incubated overnight at 4°C, washed twice with 0.01 M PBS, 5 min each time. Goat anti-rabbit IgG (HRP) antibody (Abcam) secondary antibody was incubated at room temperature for 1 h, washed twice with 0.01 M PBS, 5 min each time. The sections were stained with a DAB kit (Vector Laboratories, Inc., USA), washed three times with water, counterstained with hematoxylin for 30 seconds, and rinsed with running water for 5 minutes. They were dehydrated in a graded alcohol stream, cleared with xylene, and embedded in neutral rubber. Sections were observed under an optical microscope at 200x magnification. The results showed that the hippocampus of the mice in the blank control group (Figure 15A) expressed a certain level of BDNF (marked with an arrow), the expression of BDNF in the hippocampus of the mice in the vehicle group (Figure 15B) was significantly lower than that of the blank control group, and the expression of BDNF in the hippocampus of the mice in the treatment group (Figure 15C) was significantly higher than that of the vehicle group, with statistical differences being significant (* represents P<0.05) (Figure 15D). This indicates that plasminogen can promote the expression of BDNF in the hippocampus of Alzheimer's disease model mice. Example 14

[0094] Example 14 relates to the fact that plasminogen promotes the cleavage of NGF and the formation of mature NGF in brain homogenates from Alzheimer's disease model mice. Four 11-week-old B6SJLTg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax(FAD) (Stock number: 034840) (abbreviated as FAD) mice were selected and sacrificed to collect whole brain tissue, and brain homogenates were prepared as described above and placed in EP tubes. Eppendorf (EP) tubes were taken and five parallels were set up for each group: (1) blank control group, (2) blank group, (3) solvent control group, and (4) plasminogen group. The blank control group was added with 21.5 μL saline, 4.6 μL solvent solution (10 mM sodium citrate, 2% arginine hydrochloride, 3% mannitol, pH 7.4), and 23.9 μL mouse brain homogenate; the blank group was added with 21.5 μL saline, 4.6 μL plasminogen solution (2 mg / mL), and 23.9 μL mouse brain homogenate; the solvent control group was added with 21.5 μL Pro-NGF (Nanjing GenScript Biotechnology Co., Ltd., custom-expressed Pro-NGF, sequence derived from UniProtKB-P01138, 1.0 mg / mL), 4.6 μL of solvent solution, and 23.9 μL of mouse brain homogenate were added to the plasminogen group; 21 μL of Pro-NGF solution (1.0 mg / mL), 4.6 μL of plasminogen solution (2 mg / mL), and 23.9 μL of mouse brain homogenate were added to the plasminogen group. After adding the samples to each group, they were incubated at 37 °C for 6 hours, and then 50 μL of 0.1% trifluoroacetic acid solution was added to each group to stop the reaction. A 15% gel was prepared according to the instructions of the SDS-PAGE gel preparation kit. Each group of samples was mixed with 4× loading buffer (TaKaRa, e2139) in a volume ratio of 3:1, heated at 100°C for 5 min, cooled and centrifuged for 2 min, and then 20 μL of sample was taken for loading. The electrophoresis conditions were run at 30 V for 30 min, followed by running to the bottom of the gel at 100 V. After electrophoresis, the gel was peeled off and transferred to a PVDF membrane (GE, A29433753), and the electrophoresis conditions were 15 V for 2.5 h. The transferred PVDF membrane was immersed in a blocking solution (5% skim milk solution), blocked overnight in a refrigerator at 4 °C, washed four times with TBST (0.01 M Tris-NaCl, pH 7.6 buffer), added rabbit anti-human NGF antibody (Abcam, ab52918) and incubated at room temperature for 2 hours, washed four times with TBST, added goat anti-rabbit IgG (HRP) antibody (Abcam, ab6721) secondary antibody, incubated at room temperature for 1 hour, washed four times with TBST, placed on a clean imaging plate, added Immobilon Western HRP Substrate (MILLIPORE, WBKLS0100) for color development, photographed with a biomolecular imager, and quantitatively analyzed the band optical density with Image J. Nerve growth factor (NGF) is an important member of the neurotrophic factor family. It is synthesized in vivo in the form of a precursor that contains a signal peptide, a leader peptide, and a mature peptide. Research has reported that the precursor of nerve growth factor NGF (Pro-NGF) plays an opposing role to the NGF that is formed by cleavage. Pro-NGF can promote apoptosis of neurons. Mature NGF is involved in the regulation of processes such as neuronal growth, development, differentiation, survival, and repair after injury, and also plays an important role in regulating the functional expression of central and peripheral neurons. [8] . As a result, in the brain homogenates of Alzheimer's disease model mice, the amount of Pro-NGF was significantly lower in the plasminogen-administered group than in the vehicle control group, and the difference was highly significant (*** indicates P<0.001); the amount of NGF in the plasminogen-administered group was significantly higher than in the vehicle control group, and the difference was significant (Figure 16). This suggests that plasminogen can promote the cleavage of Pro-NGF and the formation of mature NGF in the brain homogenates of Alzheimer's disease model mice. Example 15

[0095] Example 15 relates to the fact that plasminogen promotes recovery of anxiety and depressive behavior in Alzheimer's disease model mice. 28 C57 male mice were taken and weighed before modeling. Abnormal mice were excluded based on their weight. All mice were randomly divided into two groups, 8 mice in the blank control group and 20 mice in the model group. After grouping, the Alzheimer's model was performed as in Example 6. [3] A water maze test was conducted on all mice 65 days after the brain localized injection, and the model control group was the blank control group mice. According to the results of the test, the blank control group and abnormal mice in the model group were eliminated, and the model group mice were randomly divided into two groups, 10 mice in the solvent group, 10 mice in the treatment group, and 8 mice in the blank control group. After grouping, the first period of administration was started for the mice in the solvent group and the treatment group, and plasminogen was administered to the mice in the treatment group at 50 mg / kg / mouse / day by tail vein injection, and the mice in the solvent group and the blank control group were administered with solvent (4% arginine + 2% glycine solution) at 5 ml / kg / mouse / day by tail vein injection, for 28 consecutive days. The second period of administration was started 50 days after the end of the first period of administration, and the administration method was the same as that of the first period for 7 consecutive days. An open field experiment was conducted on the 8th day of the second period of administration. Open field experiment During the experiment, the mouse was placed in the center of the bottom of the open field (40 x 40 x 40 cm), and was observed for 5 minutes with simultaneous photography and timing. Each mouse underwent three experiments. The Smart System is a complete and easy-to-use video tracking system for evaluating the behavior of experimental animals. It can record trajectories, activities, specific behaviors (turning, stretching, eating, etc.) and events, and perform calculations of various analysis parameters. In this experiment, the Smart3.0 system was used to record and analyze the mouse's movements. The parameters include the total distance traveled in the border zone and the distance traveled in the central zone. In each experiment, the box was wiped with 70% alcohol to prevent odor preference. [1] . The design principle of the open field experiment is based on mouse avoidance. This refers to the tendency of mice to "stick to the wall" because they are afraid of open, unknown, and potentially dangerous places. The total distance and average speed were considered as the main data reflecting the spontaneous activity of the mice, and avoidance was evaluated by the mouse's activity in the peripheral areas of the field (four corners and four sides). Judging from the activity time in the periphery reflecting avoidance, a shorter time indicates that the mouse tends to be more "adventurous," while a significantly longer activity time in the central zone indicates a lower level of avoidance and anxiety (depression). Percentage of travel distance in border zone The percentage of the distance traveled in the border zone is the ratio of the length of the mouse's movement track in the border zone to the total movement track length within a specified time. The results showed that the blank control group had a certain percentage of the distance traveled in the border zone, the percentage of the distance traveled in the border zone in the vehicle group mice was significantly higher than that in the blank control group, and the percentage of the distance traveled in the border zone in the treatment group mice was significantly lower than that in the vehicle group, and the statistical difference was close to significance (P=0.08) (Figure 17). This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Percentage of distance traveled in the central zone The percentage of distance traveled in the central zone is the ratio of the length of the mouse's track in the central zone to the total length of the track traveled in the central zone within a specified time. The results showed that the blank control group had a certain percentage of distance traveled in the central zone, the percentage of distance traveled in the central zone of the vehicle group mice was significantly smaller than that of the blank control group, and the percentage of distance traveled in the central zone of the treatment group mice was significantly larger than that of the vehicle group, and the statistical difference was close to significance (P=0.08) (Figure 18). This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Example 16

[0096] Example 16 relates to the fact that plasminogen promotes recovery of anxiety and depressive behavior in Alzheimer's disease model mice. 28 C57 male mice were taken and weighed before modeling. Abnormal mice were excluded based on their weight. All mice were randomly divided into two groups, 8 mice in the blank control group and 20 mice in the model group. After grouping, the Alzheimer's model was performed as in Example 6. [3] A water maze test was conducted on all mice 65 days after the brain localized injection, and the model control group was the blank control group mice. According to the results of the test, the blank control group and abnormal mice in the model group were eliminated, and the model group mice were randomly divided into two groups, 10 mice in the solvent group, 10 mice in the treatment group, and 8 mice in the blank control group. After grouping, the first period of administration was started for the mice in the solvent group and the treatment group, and plasminogen was administered to the mice in the treatment group at 50 mg / kg / mouse / day by tail vein injection, and the mice in the solvent group and the blank control group were administered with solvent (4% arginine + 2% glycine solution) at 5 ml / kg / mouse / day by tail vein injection for 28 consecutive days. The second period of administration was started 50 days after the end of the first period of administration, and the administration method was the same as that of the first period for 9 consecutive days. Two days after the end of the second period of administration, an elevated plus maze behavioral experiment was conducted. The elevated plus maze uses the animal's exploration characteristics of new and different environments and its fear of the high hanging open arms to form conflicting behaviors and examine the animal's anxiety state. The elevated plus maze has one pair of open arms and one pair of closed arms. Rodents tend to move in the closed arms because of their dark preference, but when they move in the open arms because of their curiosity and exploration and face a new stimulus, the animal feels the urge to explore and fear at the same time. This causes conflicting behaviors of exploration and avoidance, resulting in anxiety. Anti-anxiety drugs can significantly increase the number and time of entering the open arms. The plus maze is high off the ground, equivalent to standing on a cliff, which makes the subject feel fear and anxiety. The elevated plus maze is widely used in scientific research and computer-aided education in multiple fields such as new drug development / screening / evaluation, pharmacology, toxicology, preventive medicine, neurobiology, animal psychology, behavioral biology, etc., and is a classic experiment in behavioral research in medical schools and scientific research institutions, especially in the study of anxiety and depression. At the beginning of the experiment, the mouse was placed into the maze from the central grid toward the closed arm, and activity was recorded for 5 min. Observation indices included the number of open arm entries (two front paws must enter the arm), the dwell time in the open arm, the number of closed arm entries, and the dwell time in the closed arm. The percentage of the dwell time in the open arm, the percentage of the number of open arm entries, and the total number of entries in the elevated plus maze were calculated. After the experiment was over, the mouse was taken out, both arms were cleaned, and sprayed with alcohol to remove the odor. Finally, data analysis was performed using ethology software. Total distance traveled The total distance traveled refers to the length of the total movement track of the mouse within a specified recording time. As a result, the blank control group had a constant total distance traveled, the movement distance of the vehicle group was significantly greater than that of the blank control group, and the total movement distance of the treatment group was significantly smaller than that of the vehicle group, and the statistical difference was highly significant (* represents P<0.05, ** represents P<0.01) (Figure 19), and was closer to the total movement distance of the mice in the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Close arm travel distance The distance traveled in the closed arm refers to the length of the track traveled in the closed arm within a specified time. As a result, the mice in the blank control group had a certain distance traveled in the closed arm, the distance traveled in the closed arm in the solvent group was significantly larger than that in the blank control group, and the distance traveled in the closed arm in the treatment group was significantly smaller than that in the solvent group, and the statistical difference between the two groups was significant (* represents P<0.05, ** represents P<0.01) (Figure 20), and the distance traveled in the closed arm in the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Percentage of distance traveled by the closing arm The percentage of the distance traveled in the closed arm refers to the ratio of the length of the trajectory traveled in the closed arm to the length of the total trajectory traveled in a specified time. As a result, the mice in the blank control group had a certain percentage of the distance traveled in the closed arm, the percentage of the distance traveled in the closed arm in the solvent group was significantly greater than that in the blank control group, and the percentage of the distance traveled in the closed arm in the treatment group was significantly smaller than that in the solvent group, and the statistical difference between the two groups was significant (* represents P<0.05) (Figure 21), and the percentage of the distance traveled in the closed arm in the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Closed arm entries The results showed that the blank control group mice had a certain number of closed arm entries, the vehicle group's closed arm entries were significantly higher than the blank control group mice, and the administration group's closed arm entries were significantly lower than the vehicle group, and the statistical difference between the two groups was highly significant (* represents P<0.05, ** represents P<0.01) (Figure 22), and the administration group's closed arm entries were closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Close Arm Time The closed arm time is the time that the mouse stays in the closed arm within a specified time. The results showed that the blank control group mice had a constant closed arm time, the vehicle group mice's closed arm time was significantly shorter than the blank control group mice, and the administration group mice's closed arm time was significantly longer than the vehicle group, and the statistical difference between the two groups was significant (* represents P<0.05, ** represents P<0.01) (Figure 23), and the administration group's closed arm time was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Percentage of time with arms closed The percentage of closed arm time refers to the ratio of the time that the mouse stayed in the closed arm to the total time recorded. The results showed that the blank control group mice had a constant percentage of closed arm time, the percentage of closed arm time of the vehicle group mice was significantly lower than that of the blank control group mice, and the percentage of closed arm time of the treatment group mice was significantly higher than that of the vehicle group, and the statistical difference between the two groups was significant (* represents P<0.05, ** represents P<0.01) (Figure 24), and the percentage of closed arm time of the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Average speed in closed arms The average speed in the closed arm refers to the ratio of the distance traveled in the closed arm to the time spent in the closed arm. As a result, the blank control group mice had a constant average speed in the closed arm, the average speed in the closed arm of the vehicle group was significantly higher than that of the blank control group mice, and the average speed in the closed arm of the treatment group mice was significantly lower than that of the vehicle group, and the statistical difference between the two groups was highly significant (** represents P<0.01) (Figure 25), and the average speed in the closed arm of the treatment group was closer to the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Example 17

[0097] Example 17 relates to the fact that plasminogen promotes the recovery of memory function in Alzheimer's disease model mice. 28 C57 male mice were taken and weighed before modeling. Abnormal mice were excluded based on their weight. All mice were randomly divided into two groups, 8 mice in the blank control group and 20 mice in the model group. After grouping, the Alzheimer's model was performed as in Example 6. [3] A water maze test was conducted on all mice 65 days after the brain localized injection, and the model control group was the blank control group mice. According to the results of the test, the blank control group and abnormal mice in the model group were eliminated, and the model group mice were randomly divided into two groups, 10 mice in the solvent group, 10 mice in the treatment group, and 8 mice in the blank control group. After grouping, the first period of administration was started for the mice in the solvent group and the treatment group, and plasminogen was administered to the mice in the treatment group at 50 mg / kg / mouse / day by tail vein injection, and the mice in the solvent group and the blank control group were administered with solvent (4% arginine + 2% glycine solution) at 5 ml / kg / mouse / day by tail vein injection, for 28 consecutive days. The second period of administration was started 50 days after the end of the first period of administration, and the administration method was the same as that of the first period for 9 consecutive days. Two days after the end of the second period of administration, a Y-maze behavioral experiment was conducted. As a result, compared with the blank control mice, the spontaneous alternation behavior rate of the mice in the vehicle group was significantly decreased, and the spontaneous alternation behavior rate of the mice in the treatment group was significantly higher than that of the vehicle group, and the statistical difference between the two groups was significant (* represents P<0.05), and was closer to the blank control group (Figure 26). This suggests that plasminogen can promote the recovery of memory function in Alzheimer's disease model mice. Example 18

[0098] Example 18 relates to the fact that plasminogen promotes recovery of anxiety and depressive behavior in Alzheimer's disease model mice. Eighteen 20-25 week old female B6SJL-Tg(APPSwFlLon, PSEN1*M146L*L286V)6799Vas / Mmjax (purchased from Jackson lab, catalog number: 034840) mice were taken and randomly divided into two groups according to the weight and the results of the Y-maze test, with 9 mice in the vehicle group and 9 mice in the treatment group, and 9 C57 female mice of the same age were used as the blank control group. After grouping, the mice in the blank control group and the solvent group were administered with solvent (4% arginine + 2% glycine solution) at 5 ml / kg by tail vein injection, and the mice in the treatment group were administered with plasminogen at 50 mg / kg by tail vein injection, for 18 consecutive days. On the 19th day, a cross-maze behavioral experiment was performed. The results showed that the blank control group mice had a certain distance traveled in the closed arm, the distance traveled in the closed arm of the vehicle group was significantly smaller than that of the blank control group mice, and the distance traveled in the closed arm of the treatment group mice was significantly larger than that of the vehicle group, and the statistical difference between the two groups was significant (** represents P<0.01, *** represents P<0.001) (Figure 27), and the distance traveled in the closed arm of the treatment group was closer to that of the blank control group. This suggests that plasminogen can promote the recovery of anxiety and depression behavior in Alzheimer's disease model mice. Example 19

[0099] Example 19 relates to the improvement of hippocampal damage in Alzheimer's disease model mice by plasminogen. B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas / Mmjax mice (catalog number: 034840, purchased from Jackson Laboratory) and C57BL / 6J mice were backcrossed once to breed offspring (referred to as B6-F1-FAD). Eighteen 16-17 week-old female B6-F1-FAD mice and nine 9 week-old female C57BL / 6J mice were taken. B6-F1-FAD were randomly divided into two groups, a vehicle group and a treatment group, with nine mice in each group, according to their body weight and the results of the Y-maze test. Nine C57BL / 6J mice were used as a blank control group. After grouping was completed, the mice in the blank control group and the mice in the vehicle group were administered vehicle (4% arginine + 2% glycine solution) via tail vein injection, and the injection volume for each mouse was 5ml / kg. Plasminogen was administered to the mice in the treatment group via tail vein injection, with each mouse receiving a dose of 50 mg / kg for 8 consecutive days. Five days after administration, the mice were sacrificed, and brain tissue was collected and fixed in 10% neutral formaldehyde solution for 24-48 hours. The fixed brain tissue was dehydrated in an alcohol gradient, permeabilized with xylene, and then embedded in paraffin. The thickness of the sections was 3 μm. The sections were deparaffinized and rehydrated, washed once with water, stained with hematoxylin and eosin (HE staining), fractionated with 1% hydrochloric acid ethanol, blued with ammonia water, further dehydrated with an alcohol gradient, and mounted. The sections were observed under an optical microscope at 200x magnification to observe the hippocampus. As a result, the hippocampal tissue morphology of the mice in the blank control group (Figure 28A) was normal, and the tissue damage morphology of the hippocampus in the treatment group (Figure 28C) was significantly improved compared to the vehicle group (Figure 28B). This indicates that plasminogen can improve hippocampal damage in Alzheimer's disease model mice. Example 20

[0100] Example 20 relates to the therapeutic effect in Alzheimer's disease patients who voluntarily underwent plasminogen therapy. The following patients signed an informed consent form to voluntarily take the medication, and approval was obtained from the hospital ethics committee.

[0101] Patient 1, male, 76 years old, had memory problems 6 months ago, his personality became rigid, his memory and ability to learn new things declined, and he was clinically diagnosed with Alzheimer's disease. Dosage regimen: 50mg was administered intravenously at first, 10mg was added daily, and 10mg was administered by nebulization from the third day. Administration was continued once a day for 13 days. Treatment effect: The family said that during the medication process, the patient's mental state gradually improved, response sensitivity gradually and significantly improved, the patient's ability to learn new things and memory ability improved after medication, and memory was also improved. After 13 days of medication, the overall feeling of the body improved by about 50%, and memory improved by about 50%. This indicates that plasminogen can improve memory, learning ability, and mental state in Alzheimer's disease patients.

[0102] Patient 2, female, aged 96 years. Medical history: hypertension for over 20 years, no history of heart disease or diabetes. She had memory problems for about 6 months, a decline in learning ability, and a decline in thinking and communication abilities. She became irritable and apathetic. She scored 10 on the Mini-Mental State Examination (MMSE). Dosage plan: Aerosol and intravenous injection were combined. On the first day, nebulization was performed three times, 5 mg each time, and from the second day, the nebulization was started at 30 mg as before, and intravenous injection was added at 10 mg every day for 7 consecutive days. The Mini-Mental State Examination Scale (MMSE) can comprehensively, accurately and quickly reflect the subject's mental state and the degree of cognitive impairment. The scale is simple and easy to implement, and has been widely used at home and abroad, and is the preferred scale for dementia screening. Scoring criteria: score 27-30, normal; score <27, cognitive impairment; score 21-26, mild; score 10-20, moderate; score 0-9, severe. Treatment effect: 1. The spirit was improved; 2. The symptoms of senile dementia were improved and memory was improved; 3. The anxiety of the elderly was reduced; 4. The MMSE score was 14 points, which was mainly reflected in the ability to cooperate and act according to the instructions of others. The MMSE scores before and after administration are shown in Table 1. This indicates that plasminogen can improve the MMSE scores of Alzheimer's disease patients, and improve their memory, thinking ability, anxiety, and mental state. Table 1 MMSE scores before and after administration TIFF0007576861000001.tif37113

[0103] Patient 3, a woman aged 87, was admitted for examination with poor memory and comprehension, and was diagnosed by the doctor as having cerebral infarction, which affected her memory and comprehension, and showed the symptoms of senile dementia, with mild confusion and sub-mental confusion, inability to correctly identify the surrounding environment, confusion about time and place, and difficulty in communicating with others, with an overall condition score of 10 points (for the overall condition score, 10 is the first day without medication, 10 is the most severe condition yesterday after medication, 1 is the mildest condition, and 0 is normal). Dosage plan: In addition to intravenous injection of 150-250 mg, 10 mg was administered by nebulization inhalation once every 4 hours, 3 times a day, for 14 days. After 1 week off, administration was continued for 1 week, the method was the same as before, and the nebulization dose was 15 mg, once every 4 hours, 3 times a day. After 1 week off, administration was continued for another 2 weeks, every other day, 250 mg was administered by intravenous injection, and nebulization was 15 mg, once every 4 hours, 3 times a day. After that, it was changed to 400 mg intravenous injection twice a week, and 10 mg was administered by nebulization twice a day for 2 weeks. Currently, 500 mg is administered by intravenous injection once a week, and 10 mg is nebulized twice a day, 2 days a week. In the course of treatment, the above symptoms gradually improved, and after 14 days of medication, the patient's mood improved, communication with others was basically barrier-free, memory was restored, and the concept of time gradually became clearer, with an overall condition score of 4 points. 70%-80% of communication with people can be correctly understood and answered accurately. Although he often gets people's names wrong, he has no problems identifying people. This indicates that plasminogen can improve Alzheimer's disease, including improving a patient's memory, communication, cognitive, and orientation abilities.

[0104] Patient 4, a 91-year-old woman, was diagnosed with mild brain atrophy and mild cognitive impairment. The patient's memory score was 10 before medication, her numeracy score was 10, and her orientation score was 10 ((for the overall condition score, 10 is no medication on the first day, 10 is the most severe condition yesterday after medication, 1 is the mildest condition, and 0 is normal). The dosage regimen was 50-100 mg once a day by intravenous injection, plus 10 mg by nebulization, 2-3 times a day. The drug was administered once every 2 days for 13 consecutive days. Thirteen days after treatment, the patient achieved a score of 9 in self-remembering, 9 in arithmetic, and 9 in orientation. This indicates that plasminogen can improve the patient's cognitive impairment, memory, arithmetic and orientation.

[0105] Patient 5, a 79-year-old woman, had been experiencing symptoms such as memory loss and bad mood for the past 4 years, which gradually worsened. Currently, the patient is relatively quiet, has a concentration period of less than 2 minutes, impaired verbal expression, and has lost short-term memory. She is unable to distinguish between time and place, is easily sad, and has lost the ability to care for herself. She scored 3 on the MMSE. Dosage regimen: 50 mg was given by intravenous injection initially, followed by an additional 50 mg every 2 days for 14 consecutive days, then 400 mg twice a week for a total of 30 days. From the fourth day of medication, concentration and comprehension improved slightly, and on the seventh day of medication, comprehension and attention improved further, and he began to understand questions and try harder to answer them, and on the tenth day of medication, he was able to recognize and remember more objects and relatives. On the 14th day of medication, attention could be concentrated for 7-8 minutes, and memory for what had just happened could last for 6-7 minutes if the condition was good. On the 21st day of medication, he was able to concentrate for more than 30 minutes. After 24 days of medication, memory for what had just happened lasted for about 1 hour, language expression became rich, and the MMSE score was 9 points. After 30 days of medication, the MMSE score was 9 points. One month after the drug withdrawal, calculation ability improved, and the MMSE score was 8 points. The MMSE scores before and after administration are shown in Table 2. This indicates that plasminogen can improve the MMSE scores of Alzheimer's disease patients, and improve the patients' memory, cognition, attention, comprehension, verbal expression, and arithmetic abilities. Table 2. MMSE scores before and after administration TIFF0007576861000002.tif89123References: [1]Selkoe D J. Alzheimer's disease: genes, proteins, and therapy[J]. Physiol. Rev, 2001, 81 (2): 741-766. [2]Oakley H, Cole SL, Logan S, et al. Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation[J]. Journal of Neuroscience, 2006, 26(40):10129-10140. [3]Moon M , Choi J G , Kim S Y , et al. Bombycis Excrementum Reduces Amyloid-β Oligomer-Induced Memory Impairments, Neurodegeneration, and Neuroinflammation in Mice[J]. Journal of Alzheimer's disease: JAD, 2014, 41(2). [4]Park S W , Kim J H , Mook-Jung I , et al. Intracellular amyloid beta alters he tight junction of retinal pigment epithelium in 5XFAD mice[J]. Neurobiology of Aging, 2014, 35(9):2013-2020. [5]Naseri NN, Wang H, Guo J, Sharma M, Luo W. The complexity of tau in Alzheimer's disease. Neurosci Lett. 2019 Jul 13;705:183-194. [6]Gray K, Ellis V . Activation of pro-BDNF by the pericellular serine protease plasmin [J]. Febs Letters, 2008, 582(6):907-910. [7]Kowianski, Przemys?aw, Lietzau G , Czuba E , et al. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity[J]. Cellular & Molecular Neurobiology, 2017 [8]Aloe L, Rocco M L , Bianchi P , et al. Nerve growth factor: from the early discoveries to the potential clinical use[J]. Journal of Translational Medicine, 2012, 10(1).

Claims

1. A pharmaceutical composition comprising plasminogen for preventing and treating Alzheimer's disease.

2. The pharmaceutical composition according to claim 1, wherein the plasminogen has one or more activities selected from the following for a subject with Alzheimer's disease: promoting degradation of amyloid Aβ40 or Aβ42 in brain tissue; improving memory function; improving cognitive ability; improving geographic location awareness; alleviating anxiety or depression symptoms; reducing Aβ42 deposition in brain tissue; promoting the degradation of Tau protein in brain tissue; promoting the formation of mature BDNF by cleavage of Pro-BDNF in brain tissue; promoting the expression of BDNF in brain tissue; promoting the formation of mature NGF by cleavage of Pro-NGF in brain tissue; and improving hippocampal damage in brain tissue.

3. The pharmaceutical composition according to claim 1 or 2, wherein the plasminogen is human full-length plasminogen or a conservatively substituted variant thereof.

4. 4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the plasminogen has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO:2 and still has the proteolytic activity of plasminogen.

5. 4. The pharmaceutical composition of claim 1, wherein the plasminogen comprises a protein comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity to SEQ ID NO: 14 and still having the proteolytic activity of plasminogen.

6. The pharmaceutical composition according to any one of claims 1 to 3, wherein the plasminogen is selected from Glu-plasminogen and Lys-plasminogen.

7. A pharmaceutical composition described in any one of claims 1 to 6, used in combination with one or more other therapeutic methods or drugs.

8. The pharmaceutical composition of claim 7 , wherein the other therapeutic methods include cellular therapy, supportive therapy, and physical therapy.

9. 9. The pharmaceutical composition of any one of claims 1 to 8, wherein the plasminogen is administered by nasal inhalation, aerosol inhalation, nasal drops, eye drops, ear drops, intravenously, intraperitoneally, subcutaneously, intracranially, intrathecally, intraarterially, or intramuscularly.

Citation Information

Patent Citations

  • Micro plasminogen mutant with function of inhibiting platelet aggregation and preparation method and application thereof

    CN102154253A

  • Compositions and methods for enhancing structural and functional nervous system reorganization and recovery

    US20060104969A1

  • Detection and removal of misfolded proteins / peptides

    US20140044796A1

  • Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity

    WO2001058476A2

  • Method for regulating and controling GLP-1 / GLP-1r and drug

    WO2018233604A1